AU773669B2 - Mammalian cytokine: interleukin-B30 and related reagents - Google Patents

Description

AUSTRALIA

Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Applicant(s): SCHERING CORPORATION Invention Title: MAMMALIAN CYTOKINE: INTERLEUKIN-B30 AND RELATED

REAGENTS

The following statement is a full description of this invention, including the best method of performing it known to me/us: MAMMALIAN CYTOKINE: INTERLEUKIN-B30 AND RELATED REAGENTS FIELD OF THE INVENTION The present invention pertains to compositions related to proteins which function in controlling biology and physiology of mammalian cells, cells of a mammalian immune system. In particular, it provides purified genes, proteins, antibodies, and related reagents useful, to regulate activation, development, differentiation, and function of various cell types, including hematopoietic cells.

BACKGROUND OF THE INVENTION Recombinant DNA technology refers generally to the technique of integrating genetic information from a donor source into vectors for subsequent processing, such as through introduction into a host, whereby the transferred genetic information is copied and/or expressed in the new S" environment. Commonly, the genetic information exists in the form of complementary DNA (cDNA) derived from messenger RNA (mRNA) coding for a desired protein 25 product. The carrier is frequently a plasmid having the capacity to incorporate cDNA for later replication in a host and, in some cases, actually to control expression of the cDNA and thereby direct synthesis of the encoded product in the host.

For some time, it has been known that the mammalian immune response is based on a series of complex cellular interactions, called the "immune network". Recent research has provided new insights into the inner workings of this network. While it remains clear that much of the response does, in fact, revolve around the network-like interactions of lymphocytes, macrophages, granulocytes, and other cells, immunologists now generally hold the opinion that soluble proteins, known as lymphokines, cytokines, or monokines, play a critical 2 role in controlling these cellular interactions. Thus, there is considerable interest in the isolation, characterization, and mechanisms of action of cell modulatory factors, an understanding of which will lead to significant advancements in the diagnosis and therapy of numerous medical abnormalities, immune system disorders. Some of these factors are hematopoietic growth factors, granulocyte colony stimulating factor (G-CSF). See, Thomson (1994; ed.) The Cvtokine Handbook (2d ed.) Academic Press, San Diego; Metcalf and Nicola (1995) The HematoDoietic Colony Stimulatina Factors Cambridge University Press; and Aggarwal and Gutterman (1991) Human Cvtokines Blackwell Pub.

Lymphokines apparently mediate cellular activities in a variety of ways. They have been shown to support the proliferation, growth, and differentiation of pluripotential hematopoietic stem cells into vast numbers of progenitors comprising diverse cellular lineages making up a complex immune system. Proper and balanced interactions between the cellular components are necessary for a healthy immune response. The different cellular lineages often respond in a different manner whe. lymphokines are administered in conjunction with 25 other agents.

Cell lineages especially important to the immune response include two classes of lymphocytes: B-cells, which can produce and secrete immunoglobulins (proteins with'the capability of recognizing and binding to foreign matter to effect its removal), and T-cells of various subsets that secrete lymphokines and induce or suppress the B-cells and various other cells (including other Tcells) making up the immune network. These lymphocytes interact with many other cell types.

Another important cell lineage is the mast cell (which has not been positively identified in all mammalian species), which is a granule-containing connective tissue cell located proximal to capillaries throughout the body. These cells are found in especially 3 high concentrations in the lungs, skin, and gastrointestinal and genitourinary tracts. Mast cells play a central role in allergy-related disorders, particularly anaphylaxis as follows: when selected antigens crosslink one class of immunoglobulins bound to receptors on the mast cell surface, the mast cell degranulates and releases mediators, histamine, serotonin, heparin, and prostaglandins, which cause allergic reactions, anaphylaxis.

Research to better understand and treat various immune disorders has been hampered by the general inability to maintain cells of the immune system in vitro. Immunologists have discovered that culturing these cells can be accomplished through the use of T-cell 15 and other cell supernatants, which contain various growth factors, including many of the lymphokines.

From the foregoing, it is evident that the discovery and development of new lymphokines, related to G- CSF and/or IL-6, could contribute to new therapies for a 20 wide range of degenerative or abnormal conditions which directly or indirectly involve the immune system and/or hematopoietic cells. In particular, the discovery and development of lymphokines which enhance or potentiate the beneficial activities of known lymphokines would be 25 highly advantageous. The present invention provides new interleukin compositions and related compounds, and methods for their use.

SUMMARY OF THE INVENTION The present invention is directed to mammalian, rodent, canine, feline, primate, and its biological activities. It includes nucleic acids coding for poiypeptides themselves and methods for their production and use. The nucleic acids of the invention are characterized, in part, by their homology to cloned complementary DNA (cDNA) sequences enclosed herein, and/or by functional assays for growth factor- or cytokine-like activities, G-CSF (see Nagata (1994) in Thomson The Cytokine Handbook 2d ed., 4 Academic Press, San Diego) and/or IL-6 (see Hirano (1994) in Thomson The Cytokine Handbook 2d ed., Academic Press, San Diego), applied to the polypeptides, which are typically encoded by these nucleic acids. Methods for modulating or intervening in the control of a growth factor dependent physiology or an immune response are provided.

The present invention is based, in part, upon the discovery of a new cytokine sequence exhibiting significant sequence and structural similarity to G-CSF and IL-6. In particular, it provides primate, e.g., human, gene encoding a protein whose mature size is about 168 amino acids, and pig and murine, mouse, sequences. Functional equivalents exhibiting significant sequence homology will be available from other mammalian, cow, horse, and rat, and non-mammalian species.

In a first aspect, the invention provides a substantially pure or isolated polypeptide, which comprises: a) at least 148 contiguous amino acids from the mature polypeptide of SEQ ID NO: 2; b) at least 17 contiguous amino acids from the mature polypeptide of SEQ ID NO: 4; or c) at least 30 contiguous amino acids from the mature polypeptide of SEQ ID NO: In a second aspect, the invention provides a substantially pure or isolated polypeptide comprising the mature polypeptide of SEQ ID NO: 2.

There is provided: a substantially pure or 30 recombinant IL-B30 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 2; a natural sequence IL-B30 of SEQ ID NO: 2; and a fusion protein comprising sequence. In certain embodiments, the homology is at least about 90% identity and the portion is at least about 9 amino acids; the homology is at least about identity and the portion is at least about 17 amino acids; 0 0 0 0 0 0 000.0 0.0.0 00 00 00000 5 or the homology is at least about 70% identity and the portion is at least about 25 amino acids. In other embodiments, the IL-B30: comprises a mature sequence of Table 1; or exhibits a post-translational modification pattern distinct from natural IL-B30; or the protein or peptide: is from a warm blooded animal selected from a mammal, including a primate: comprises at least one polypeptide segment of SEQ ID NO: 3; exhibits a plurality of portions exhibiting the identity; is a natural allelic variant of IL-B30; has a length of at least about 30 amino acids; exhibits at least two non-overlapping epitopes which are specific for a mammalian IL-B30; exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to mammalian IL-B30; is glycosylated; has a molecular weight of at least 10 kD with natural glycosylation; is a synthetic polypeptide; is attached to a solid substrate; is conjugated to another chemical moiety; is a 5-fold or less substitution from natural sequence; or is a deletion or insertion variant from a natural sequence. Preferred embodiments include a composition comprising: a sterile IL-B30 protein or peptide; or the IL-B30 protein or peptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration. In fusion protein embodiments, the protein can have: mature protein sequence of Table 1; a detection or purification tag, including a FLAG, His6, or Ig sequence; and/or sequence of another cytokine or chemokine.

Kit embodiments include those with an IL-B30 protein or polypeptide, and: a compartment comprising the protein or polypeptide; and/or instructions for use or disposal of reagents in the kit.

In a third aspect, the invention provides a binding 35 compound which: 1) specifically binds the mature polypeptide of *SEQ ID NO: 2; 6 2) specifically binds to the mature polypeptide of SEQ ID NO: 4; 3) specifically binds to the mature polypeptide of SEQ ID NO: 4) is raised against a purified or recombinantly produced IL-B30 protein; is raised against a purified or recombinantly produced mouse IL-B30 protein; or 6) is raised against a purified or recombinantly produced pig IL-B30 protein.

In binding compound embodiments, the compound may have an antigen binding site from an antibody, which specifically binds to a natural IL-B30 protein, wherein: the IL-B30 is a mammalian protein; the binding compound is an Fv, Fab or Fab2 fragment; the binding compound is conjugated to another chemical moiety; or the antibody: is raised against a peptide sequence of a mature polypeptide of Table 1; is raised against a mature IL-B30 is raised to a purified rodent IL-B30; is immunoselected; is a polyclonal antibody; binds to a denatured IL-B30; exhibits a Kd of at least 30 pM; is attached to a solid substrate, including a bead or plastic membrane; is in a sterile composition; or is detectably labeled, including a .radioactive or fluorescent label. Kits containing binding 25 compounds include those with: a compartment comprising the binding compound; and/or instructions for use or disposal S.of reagents in the kit. Often the kit is capable of making a qualitative or quantitative analysis. Preferred compositions will comprise: a sterile binding compound; or the binding compound and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, *topical, or parenteral administration.

In a fourth aspect, the invention provides an 35 isolated or recombinant polynucleotide encoding a polypeptide comprising: 7 a) at least 148 contiguous amino acids from the mature polypeptide of SEQ ID NO 2; b) at least 17 contiguous amino acids from the mature polypeptide of SEQ ID NO: 4; or c) at least 30 contiguous amino acids from the mature polypeptide of SEQ ID NO: In a fifth aspect, the invention provides an isolated or recombinant polynucleotide encoding a polypeptide comprising the mature polypeptide of SEQ ID NO: 2.

Nucleic acid embodiments include an isolated or recombinant nucleic acid encoding an IL-B30 protein or peptide or fusion protein, wherein: the IL-B30 is from a mammal; and/or the nucleic acid: encodes an antigenic peptide sequence of Table 1; encodes a plurality of antigenic peptide sequences of Table 1; exhibits at least about 80% identity to a natural cDNA encoding the segment; is an expression vector; further comprises an origin of replication; is from a natural source; comprises a detectable label; comprises synthetic nucleotide sequence; is less than 6 kb, preferably less than 3 kb; is from a mammal, including a primate; comprises a natural full length coding sequence; is a hybridization probe for a gene encoding the IL-B30; or is a PCR primer, PCR product, or mutagenesis primer. The invention also provides a cell, tissue, or organ comprising such a recombinant nucleic acid, and preferably the cell will be: a prokaryotic cell; a eukaryotic cell; a bacterial cell; a yeast cell; an insect cell; a mammalian cell; a mouse :cell; a primate cell; or a human cell.

Kit embodiments include those with such nucleic acids, and: a compartment comprising a nucleic acid; a compartment further comprising the IL-B30 protein or polypeptide; and/or instructions for use or disposal of reagents in the kit. Typically, the kit is capable of 35 making a qualitative or quantitative analysis.

To certain embodiments, the nucleic acid: hybridizes under wash conditions of 300 C and less than 2M salt, or of 7a 450 C and/or 500 mM salt, or 550 C and/or 150 mM salt, to SEQ ID NO: 1; or exhibits at least about 85% identity and/or the stretch is at least about 30 nucleotides, or exhibits at least 90% identity and/or the stretch is at least 55 nucleotides, or exhibits at least 95% and/or the stretch is at least 75 nucleotides, to a primate In a sixth aspect, the invention provides use of an agonist or antagonist of a mammalian IL-B30, wherein said mammalian IL-B30 comprises the mature polypeptide of SEQ ID NO: 2, 4, or 5 in the manufacture of a medicament for modulating physiology or development of a cell or tissue culture cells.

In a seventh aspect, the invention provides a method of modulating physiology or development of a cell or tissue culture cells comprising contacting the cell or tissue culture cells with an agonist or antagonist of a mammalian IL-B30, wherein the mammalian IL-B30 comprises the mature polypeptide of SEQ ID NO: 2, 4 or The invention embraces a method of modulating physiology or development of a cell or tissue culture cells comprising contacting the cell with an agonist or antagonist of a mammalian IL-B30. The method may be where: the contacting is in combination with an agonist or antagonist of G-CSF and/or IL-6; or the contacting is with an antagonist, including a binding composition comprising an antibody binding site which specifically binds an IL- DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS All references cited herein are incorporated herein ::by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

*o I. General The present invention provides amino acid sequences 7b and DNA sequences encoding various mammalian proteins which are cytokines, which are secreted molecules which can mediate a signal between immune or other cells.

See, Paul (1994) Fundamental Immunology (3d ed.) Raven Press, N.Y. The full length cytokines, and fragments, or antagonists will be useful in physiological modulation of cells expressing a receptor. It is likely that IL-B30 has either stimulatory or inhibitory effects on hematopoietic cells, including, lymphoid cells, such as T-cells, B-cells, natural killer (NK) cells, macrophages, dendritic cells, hematopoietic progenitors, etc. The proteins will also be useful as antigens, e.g., immunogens, for raising antibodies to various epitopes on the protein, both linear and conformational epitopes.

A cDNA encoding IL-B30 was identified from a human cell line. The molecule was designated huIL-B30. A related gene corresponding to a pig sequence was also identified. A rodent sequence, from mouse, is also described.

The human gene encodes a small soluble cytokine-like protein, of about 168 amino acids. The signal sequence *99 *eeo **eo *e e probably is about 21 residues, and would run from the Met to about Ala. See Table 1 and SEQ. ID. NO: 1 and 2. ILexhibits structural motifs characteristic of a member of the long chain cytokines. Compare, IL-B30, G- CSF, and IL-6, sequences available from GenBank. See also Table 2.

Table 1: Nucleic acid (SEQ ID NO: 1) encoding IL-B30 from a primate, e.g., human. Translated amino acid sequence is SEQ ID NO: 2.

ATG

48 Met -21

GCT

96 Ala -5

CTG

Leu -20

CAG

Gin Cly Ser Arg Ala Val Met -15 CCC AGA GCT GTG CCT GGG Gly Arg Ala Val Pro Gly Leu Leu Leu Leu

CCT

Pro CCC AC Gly Ser 5 TGC ACA Cvs Thr GGG AGC AGA GCT GTA ATO CTG CTG TTG CTG CTGCcc TGG ACA

AGC

Ser Leu Pro Trp Thr CC TGG ACT CAG Ala Trp Thr Gin TGG AGT GCA CAT Trp Ser Ala His TGC CAG CAG CTT1 TCA CAG AAG CTC 144 Cys Gin Gin Leu Ser Gin Lys Leu CCA CTA GTG GGA CAC ATG CAT CTA 192 Pro Leu Val Gly His Met Asp Leu CTG GCC Leu Ala Ara ACA AAT 240 Thr Asn CAT GTT Asp Val AGG GAC Arg Asp CCC CAT ATC Pro His :1e AAC ACT CAC Asn Ser Gin-

CAG

C 1.

TOT

GAA GAG CGA GAT CAA GAG ACT G.u Clu Cly Asp Clu Clu Thr CGA CAT GGC TGT CAC CCC CAA 01,; Asp Gly Cys Asp Pro Gin

GGA

288 G Iy 60

CTG

336 Leu

CTC

Leu T- T CA.A AGG Cyz :,eu G In Ar g 7 0 ATT TTT TAT GAG :le Phe Tyr Glu 8 0 AAG CTG C7A OGA TCG Lys Leu C':v ;er CAT ATT Asp Ile ATC CAC CAG GOT :1e His Gin Gly TTC ACA CCC GAG Phe Thr Cly Ciu CAT CCC TCC CTA His Ala Ser Leu CCT TCT CTG CTC 384 Pro Ser Leu Leu CTG CCC CTC AGC 432 Leu Gly Leu Ser 110 CAG CAG ATT CCA 480 CCT A=O C'7 Pro Asp Ser pr-- ra I CAA CT7 CAG C= Gin Leu Zeu Gin Pro ACC CTC ACT CCC AC

CG

Ala

CAG

Gin CT17 Le u GAG OCT Giu Cly CAC CCA 105 CAC CAC TOO GAG ACT His His Trp Ciu Thr

TOG

120 CAG COT CTC CTT Gin Gin Ile Pro Ser Ser Pro Ser Gin Pro Trp Gin Arg Leu Leu 125 13C 135 CTC CGC TTC AAA ATC CTT CGC AGC CTC CAG GCC TTT GTG GCT GTA GC 528 Leu Arg Phe Lys Ile Leu Arg Ser Leu Gin Ala Phe Val Ala Val Ala 140 145 150 155 GCC CGG GTC TTT GCC CAT GGA GCA GCA ACC CTG AGT CCC TAA 570 Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Ser Pro 160 165 coding sequence:

ATGCTGGGGA

TCAGGGCAGA

AGCAGCTTTC

GTGGGACACA

TGTTCCCCAT

ACAACAGTCA

GAGAAGCTGC

TGATAGCCCT

TCCTGCAGCC

AGTCCCAGCC

CAGCCTCCAG

CAGCAACCCT

GCAGAGCTGT

GCTGTGCCTG

ACAGAAGCTC

TGGATCTAAG

ATCCAGTGTG

GTTCTGCTTG

TAGGATCGGA

GTGGCGCAGC

TGAGGGTCAC

AGCCATGGCA

GCCTTTGTGG

GAGTCCCTAA

AATGCTGCTG

GGGGCAGCAG

TGCACACTGG

AGAAGAGGGA

GAGATGGCTG

CAAAGGATCC

TATTTTCACA

TTCATGCCTC

CACTGGGAGA

GCGTCTCCTT

CTGTAGCCGC

TTGCTGCTGC

CCCTGCCTGG

CCTGGAGTGC

GATGAAGAGA

TGACCCCCAA

ACCAGGGTCT

GGGGAGCCTT

CCTACTGGGC

CTCAGCAGAT

CTCCGCTTCA

CCGGGTCTTT

CCTGGACAGC

ACTCAGTGCC

ACATCCACTA

CTACAAATGA

GGACTCAGGG

GATTTTTTAT

CTCTGCTCCC

CTCAGCCAAC

TCCAAGCCTC

AAATCCTTCG

GCCCATGGAG

Rodent, e.g. mouse, IL-B30 (SEQ ID NO: 3 and 4) CGCTTAGAAG TCGGAOTACA GAGTTAGACT CAGAACCAAA GGAGGTGGAT AGGGGGTCCA CAGGCCTGGT GOAGATCACA GAGOCAGCOA GATCTGAGAA GCAGGGAACA AG ATG Met -21 115 -o.

*o 4.

-TG GAT Leu Asp TGC AGA GCA Cys Arg Ala

GTA

Val -15 ATA ATG CTA TGG :le Met Leu Trp CTG TTG Leu Leu -i0 CCC TGG GTC Pro Trp Val ACT 163" Thr CAG GCO CTG CT GTG COT AGG AGT AGO AGT CCO GAO TGG GOT CAG TC Gin Gly Leu Ala Val Pro Arg Ser Ser Ser Pro Asp Trp Ala Gin Cys CAG CAG CTC TOT Gin G-n Leu Ser CCC AAT OTO Arg Azr. Leu A-cc Cys 20 ATO OTA CCC TGG Me', Leu Ala Trp

A.AC

Asn GCA CAT GCA Ala His Ala OCA GC Pro Ala GGA CAT ATG AAT OTA CTA AGA CAA GAA GAG CAT GAA GAG ACT ClY His Met Asn Leu Leu Ara- Clu Glu Glu Asp Glu Clu Thr

AAA

Lys 4 S AAT AAT COG CCC Asn Asn Val Pro

CGT

Arg 50 ATO CAG TO-T CAA :le Gin Cys Glu

CAT

Asp GGT TCT CAC OCA Cly Cys Asp Pro GGA COO A.AG GAO Gly LTeu LYS Asp

AAC

Asn AGO CAC TTC TGO Ser Gin Phe Cys CAA AGC ATC CC Gin Arg Ile Arg CAA GGT Gin Gly CTG GOT TTT Leu Ala Phe AAC CAC CTG CTT Lys His Leu Leu

GAO

Asp TOT GAO ATO TO Ser Asp Ile Phe AAA CCC GAG Lys Cly Clu CCT GCT CTA Pro Ala Leu CTA GGA CTC Leu Gly Leu CTC CCT GAT AGC Leu Pro Asp Ser

CCC

Pro 100

CAG

Gin ATG GAG CAA CTT Met Glu Gin Leu ACC TCC CTA Thr Ser Leu CGG GAG ACC Arg Glu Thr AGC CAA CTC Ser Gin Leu 110

CTC

Leu 115

AGT

Ser CCA GAG GAT Pro Glu Asp

CAC

His 120

TGG

Trp

CAA

Gin 125

CTC

Leu

CAG

Gin ATG CCC AGC Met Pro Ser

CTG

Leu 130

CTT

Leu TCT AGT CAG Ser Ser Gin

CAG

Gin 135

GCC

Ala CAG CGC CCC Gin Arg Pro CGT TCC AAG Arg Ser Lys

ATC

Ile 145

GCC

Ala CGA AGC CTC Arg Ser Leu

CAG

Gin 150

ACT

Thr TTT TTG GCC Phe Leu Ala ATA GCT Ile Ala 155 TTA GTG Leu Val GCC CGG GTC TTT Ala Arg Val Phe CAC GGA GCA GCA His Gly Ala Ala CTG ACT GAG CCC Leu Thr Giu Pro 170 CCA ACA GCT Pro Thr Ala TAAGGATGCC CAGGTTCCCA TGGCTACCAT GATAAGACTA

S

S.

ATCTATCAGC

TCCT-'TTT

30 GAGCAGOCAG

CCTTGGAAGC

CTGTGAGAAA

AAAAACAAGA

iACACTACTCC 40 TAOTCACTAA

CCAGACATCT

TGCGTGAAGG

CTGGCTAGAG

GGGCAAGCAG

ACCCAGAGCA

AAAGGGGAAC

AGACAGCAGC

GAACTAACAG

ACCAGTTAAT

GCAAGGACAC

AALAGGAGCTG

CTGCCTGGCC

TCAGAAAAAG

A'.'ATACTTT

TCTGTACCTO

GACTACCAAr TAACCCATTA GGACTTGTGC CATTATTAAA GAGAAAAGAA GAGAAGAAGA ATAAAGTCTC TGAGGGGAAG GGGGCGGTGG TGAGCCCAGG CTTTGGCCAT CCTGGGTGGC TCAGGGAAAT CCrTGCTCTCT CCCTCAGTTC ACGAACTGAC AAA

TGTTCTTGTT

ACAAACCCCA

GAGCCCTTGG

CATCGAGAAA

TATCTGTAAG

GTGCAGATGC

TAACAGAATC

800 860 920 980 1040 1100 1160 1203 Table 2: Comparison of various IL-6 and G-CSF embodiments compared to IL-B30. Human IL-B30 is SEQ ID NO: 2; mouse IL-B30 is SEQ ID NO:4; pig IL-B30 is SEQ ID NO: 5; bovine G-CSF is SEQ ID NO: 6; feline G-CSF is SEQ ID NO: 7; human G-CSF is SEQ ID NO: 8; mouse G-CSF is SEQ ID NO: 9; otter IL-6 is SEQ ID NO: 10; feline IL-6 is SEQ ID NO: 11; human IL-6 is SEQ ID NO: 12; sheep IL-6 is SEQ ID NO: 13; mouse IL-6 is SEQ ID NO: 14; chicken MGF is SEQ ID NO: and KSHV, kaposi's sarcoma herpes virus, a viral IL-6, is SEQ ID NO: 16.

i130_human i130_mouse i130..pig gcsf-bovin gcsf-felca gcsf-human gcsf -mouse i16_otter i16_felca i16-human i16 sheep i2.6_mouse 25 mgf chick ilE-khsv il3C-humar.

i130_mouse 30 i130_.pig gcsf-bovin gcsf_felca gcsf-human gcsf_mouse 35 i16_otter i7 6 felca iIL6 human it 6sneep mouse 40 rrg, chick i.6 frsv il3C -iuman~ i130_mouse i.130..pig gcsf-bovin gcs f.felca gcs f..human gcs fMouse so ilE6-otter i16-felca 116_human 11-6_mouse mnqf -chick 6_khsv

TPLG

TPLG

TPLG

VPLVTVSALP

.AFPTPGPLG

.AFPTPGPLG

AFPAPVPPG

AFPTPGPLG

.AFPTSQVRF.

AR

TS

AS

SL

GDSKDDATSN

G. DATSN

EDSKDVAAPH

EDFKNDTTPS

GDFTEDTTPN

APLAELSGD

.TRG

SLPQSFLLKC

SLPQSFLLKC

SLPQSFLLKC

PLPRSFLLKS

RPPLTSADKM

RLPLTPADKM

RQPLTS SERI

RLLLTTPEKT

R. PVrYTTSQV

HDFQLFLHKN

KLPDAPEFEK

HMD. LREEG DEETTNDVPH I. QCGDGC DPQGLRDNSQ HMNLLREEE DEETKNNVPR QCEDGC DPQGLKDNSQ VPGG SSPVWTQCQQ LSQKLCT.LA WSAHPLVG..

VPRS S.SPDWA.QCQQ LSRNLCM. LA WNAHAPAG.

LEQVR.K..I.QA.D

LEQVRKVQAD

LEQVRKIQGD

LEQVRKIQAS

EDFIKFILGK

EELIKYILGK

DKQIRYILDG

EALIKH-IVDK

GGLITHVLWE

LEFTRKIRGD

DLL IQRLNWM CkA L..

CAA. HKLC.H .ECAA HKLCI-i

ECAT.YKLCH-

CD YKC

.CDK.YNKCE

.CNK. SNCE

.CEK.NCE

CEN JDEC CDT. FQLDCT LCYF.. TGICK I FYEKLLGSD

AFYKHL.LDSD

VFYEKLLGSD

FLYOGLLQAZ,

FLYQGLL0AL

FLYQGLLQA'-

CLYOGLLQAL

QEFQI HLKYL

QEFQIYLKFL

LEFEVYLEY:..

LEYQIYLDFL

LEYHSYLEYM

I{AYHDS LGAV,

PEELMLLRHS

PEELVLLGHA

PEELVLLG1HS

PEELVLLGHS

DSKEVLAENN

DSKEALAENN

SSKEALAENN

NSKRET LAENK

NNDDALAENN

EELQLVQPD

C-ILEPAAIFH

FTGE

IFFGE..,

I FTGE

AGIS..

AGIS SCIS ESNYEG 4 QDKYEG. D QNRFES S QNEFEG KNNLKDIN. 1

L.RLLP'..

TTEFGRSV:N

LGIP.QAPLS

LGIP.QAPLS

LGIP .WAPLS LGIP. KASLS

LNLPKLAEKD

LNLPKLAEKD

LNLPKMAEYD

LKLPT(MEEKD

LKLPE:QRhD PHLV. QAPLD

TPAINDTD

PSL..PDSPV

PALIJPDSPM

PSLHPDGSV

PELAPTLDT

PELAPTLDM

PELGPTLDT

PALAPTLDL

KDNAH-SVYI S

KENAKSXTYTS

EEQARAVQMS

QETVMELQSS

KDKARVLQRD

.NHTTLVET

VD\TME-LLTKT

SC S. LQLR. SCS SQALQLT

SCPSQALQLA

GCSSQALQQT

RCFQSRFNQE

GCFQSGFNQE

GCFQSGFNEE

GCFQSGFNQA

GCYQTGYNQE

QCHKRGFQAE

HCGLIGFNET

AQLHASLLGL

EQLHTSLLGL

GQLHASLLGL

LQLDVTDFAT

LQLDITDFAI

LQLDVADFAT

LQLDVANFAT

TKHLLQTLRP

TNVLLQMLKR

TKVLIQFLQK

IRTLIQI LKE

TETLIHIFNQ

LQLDAANLSS

LGWDIQEELN

GAELQERL..

GTALQERL..

GAALQEKLVS

GSVLLEQL..

ISALRNEM..

ISALKKEM..

ISALRKET..

ISAIRKEI..

IVEMRKEL..

VAALQRAV..

LWVIDECFRD

FCLQRIHQGL

FCLQRIRQGL

SCLQRIHQGL

GCLNQLHGGL

GCLRQLHSGL

GCLSQLHSGL

QCLSQLHSGL

TCLTRITTGL

TCLTRITTGL

TCLVKI ITGL

ICLIKTTAGL

ICLLKISSGL

VCFTQIRAGL

SCLKKLADGF

SQLLQPE. .G SQLLQPE. .D RQLLQPE. .G

NIWLQMEDLG

NIWQQMEDVG

TIWQQMEELG

T IWQQMENLG M. .NQIEVTT KGKNQDEVT I

KAKNLDAITT

KIA.

EVKDLHKIVL

NI QQQMEDLG KLTKTHY. .S Table 2 (continued) i130_human i130_mouse il3Q..pig gcsf_bovin gcsf_felca gcsf-human gcsf_mouse ilE-otter i16_felca i16_human ilE-sheep i16_mouse mgfchick i16_khsv i130_human i130_mouse 20 i13..pig gcsf_bovin gcsf-felca gcsf'_human gcsf_mouse i16_otter i16_felca i16_human ilE-sheep i16_mouse mgt..chick il6-khsv HHWETQQIP

HPRETQQMP.

HHWETEQTP.

AAPAVQPTQ.

MAPAVPPTQ.

MAPALQPTQ.

VAPTVQPTQ.

PDPTTDASL.

PVPTVEVGL.

PDPTTNASL.

TTPATHTDM.

PTPISNALL.

LDTVTLPAEQ

P.PKFDRG.

TLSP....

TLTEPLVPTA

TLSQ p p .SLSPSQ. .P .SLSSSQ. .Q .spspsQ.. p

.GAMPTFTSA

GTMPTFTSA

GAMPAFASA

SAMPAFTSA

QALFKSQDK

.QLSCSHR.R

LTKLQAQNQ

LEKMQSSNE

TDKLESQKE

RSPPPTFSGP

LLGRLQGLKY

WQRLLLRFKI

WQRPLLRSKI

WQRLLLRLKI

FQRRAGGVLV

FQRRAGGTLV

FQRRAGG-VLV

FQRRAGGVLA

WLKHTTIHLI

VAEAHNN}ILT

WLQDMTTHLI

WVKNAKVI II

WLRTKTIQFI

FQQQVGGFFI

WVRHFASFYV

LRSLOAFVAV

LRSLQAFLAI

LRSLQAFVAV

ASQLHRFLEL

ASNLQSFLEV

ASHLQSFLEV

I SYLQGF LET

LRRLEDFLQF

LRRLEDFLQL

LRSFKEFLQS

LRSLENFLQF

LKSLEEFLKV

LANFQRFLET

LSAMEKFAGQ

AARVFAHGAA

AARV'FAHGAA

AARV'FAHGAA

AYRGLRYLAE

AYRALRHFTK

SYRVLRH LAQ

ARLALHHLA.

SLRAIRIM..

RLRAVRIM..

SLRALRQM..

SLRAIRMK..

TLRSTRQT..

AYRALRHLAR

AVRVLDSIPD

*ee.

L

VTPDVHDI(

The structural homology of IL-B30 to related proteins suggests related function of this molecule. IL-B30 is a long chain cytokine exhibiting sequence similarity to IL-6 and G-CSF.

IL-B30 agonists, or antagonists, may also act as functional or receptor antagonists. e.g. which block IL- 6 or G-CSF binding to their respective receptors, or mediating the opposite actions.

Thus, IL-B30, or its antagonists, may be useful in the treatment of abnormal medical conditions, including immune disorders, T cell immune deficiencies, chronic inflammation, or tissue rejection, or in cardiovascular or neurophysiological conditions.

The natural antigens are capable of mediating various biochemical responses which lead to biological or physiological responses in target cells. The preferred embodiment characterized herein is f rom human, but other primate, or other species counterparts exist in nature.

13 Additional sequences for proteins in other mammalian species, primates, canines, felines, and rodents, should also be available. See below. The descriptions below are directed, for exemplary purposes, to a human IL-B30, but are likewise applicable to related embodiments from other species.

II. Purified Human IL-B30 amino acid sequence, is shown as one embodiment within SEQ ID NO: 2. Other naturally occurring nucleic acids which encode the protein can be isolated by standard procedures using the provided sequence, PCR techniques, or by hybridization.

These amino acid sequences, provided amino to carboxy, 15 are important in providing sequence information for the cytokine allowing for distinguishing the protein antigen from other proteins and exemplifying numerous variants.

Moreover, the peptide sequences allow preparation of peptides to generate antibodies to recognize such 20 segments, and nucleotide sequences allow preparation of oligonucleotide probes, both of which are strategies for i. detection or isolation, cloning, of genes encoding such sequences.

As used herein, the term "human soluble 25 shall encompass, when used in a protein context, a protein having amino acid sequence corresponding to a soluble polypeptide shown in SEQ ID NO: 2, or significant fragments thereof. Preferred embodiments comprise a plurality of distinct, nonoverlapping, segments of 3C the specified length. Typically, the plurality will be at least two, more usually at least three, and preferably 7, or even more. While the length minima are provided, longer lengths, of various sizes, may be appropriate, one of length 7, and two of length 12.

Binding components, antibodies, typically bind to an IL-B30 with high affinity, at least about 100 nM, usually better than about 30 nM, preferably better than about 10 nM, and more preferably at better than about 3 nM. Counterpart proteins will be found in mammalian species other than human, other primates, ungulates, or rodents. Non-mammalian species should also possess structurally or functionally related genes and proteins, birds or amphibians.

The term "polypeptide" as used herein includes a significant fragment or segment, and encompasses a stretch of amino acid residues of at least about 8 amino acids, generally at least about 12 amino acids, typically at least about 16 amino acids, preferably at least about 20 amino acids, and, in particularly preferred embodiments, at least about 30 or more amino acids, 35, 40, 45, 50, etc. Such fragments may have ends which begin and/or end at virtually all positions, beginning at residues 1, 2, 3, etc., and ending at, 150, 149, 148, etc., in all practical 15 combinations. Particularly interesting peptides have ends corresponding to structural domain boundaries, e.g., helices A, B, C, and/or D. See Table 1.

The term "binding composition" refers to molecules that bind with specificity to IL-B30, in an 20 antibody-antigen interaction. The specificity may be more or less inclusive, specific to a particular embodiment, or to groups of related embodiments, e.g., primate, rodent, etc. It also includes compounds, e.g., proteins, which specifically associate with 25 including in a natural physiologically relevant proteinprotein interaction, either covalent or non-covalent.

The molecule may be a polymer, or chemical reagent. A functional analog may be a protein with structural modifications, or it may be a molecule which has a molecular shape which interacts with the appropriate binding determinants. The compounds may serve as agonists or antagonists of a receptor binding interaction, see, Goodman, et al. (eds.) Goodman Gilman's: The Pharmacological Bases of Therapeutics (current ed.) Pergamon Press.

Substantially pure, in a protein context, typically means that the protein is free from other contaminating proteins, nucleic acids, or other biologicals derived from the original source organism.

Purity may be assayed by standard methods, typically by weight, and will ordinarily be at least about 40% pure, generally at least about 50% pure, often at least about pure, typically at least about 80% pure, preferably at least about 90% pure, and in most preferred embodiments, at least about 95% pure. Carriers or excipients will often be added.

Solubility of a polypeptide or fragment depends upon the environment and the polypeptide. Many parameters affect polypeptide solubility, including temperature, electrolyte environment, size and molecular characteristics of the polypeptide, and nature of the solvent. Typically, the temperature at which the polypeptide is used ranges from about 4° C to about 650 C. Usually the temperature at use is greater than about 15 18° C. For diagnostic purposes, the temperature will usually be about room temperature or warmer, but less than the denaturation temperature of components in the assay. For therapeutic purposes, the temperature will usually be body temperature, typically about 370 C for humans and mice, though under certain situations the temperature may be raised or lowered in situ or in vitro.

The size and structure of the polypeptide should *generally be in a substantially stable state, and usually not in a denatured state. The polypeptide may be 25 associated with other polypeptides in a quaternary structure, to confer solubility, or associated with lipids or detergents.

The solvent and elecarolytes will usually be a biologically compatible buffer, of a type used for preservation of biological activities, and will usually approximate a physiological aqueous solvent. Usually the solvent will have a neutral pH, typically between about and 10, and preferably about 7.5. On some occasions, one or more detergents will be added, typically a mild nondenaturing one, CHS (cholesteryl hemisuccinate) or CHAPS (3-[3-cholamidopropyl)dimethylammonio]-1-propane sulfonate), or a low enough concentration as to avoid significant disruption of structural or physiological properties of the protein. In other instances, a harsh detergent may be used to effect significant denaturation.

III. Physical Variants This invention also encompasses proteins or peptides having substantial amino acid sequence identity with the amino acid sequence of the IL-B30 antigen. The variants include species, polymorphic, or allelic variants.

Amino acid sequence homology, or sequence identity, is determined by optimizing residue matches, if necessary, by introducing gaps as required. See also Needleham, et al. (1970) J. Mol. Biol. 48:443-453; Sankoff, et al. (1983) Chapter One in Time Warps, String Edits, and Macromolecules: The Theory and Practice of Seauence Comparison, Addison-Wesley, Reading, MA; and see* software packages from IntelliGenetics, Mountain View, 15 CA; and the University of Wisconsin Genetics Computer Group, Madison, WI. Sequence identity changes when considering conservative substitutions as matches.

Conservative substitutions typically include *substitutions within the following groups: glycine, 20 alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; :lysine, arginine; and phenylalanine, tyrosine. The conservation may apply to biological features, functional features, or structural features. Homologous amino acid 2 sequences are typically intended to include natural polymorphic or allelic and intersoecies variations of a protein sequence. Typical nomoiogous proteins or peptides will have from 25-100% identity (if gaps can be introduced), to 50-100% identity (if conservative substitutions are included) with the amino acid sequence of the IL-B30. Identity measures will be at least about generally at least about 40%, often at least about typically at least about 60%, usually at least about preferably at least about 80%, and more preferably at least about The isolated IL-B30 DNA can be readily modified by nucleotide substitutions, nucleotide deletions, nucleotide insertions, and inversions of short nucleotide stretches. These modifications result in novel DNA sequences which encode these antigens, their derivatives; or proteins having similar physiological, immunogenic, antigenic, or other functional activity. These modified sequences can be used to produce mutant antigens or to enhance expression. Enhanced expression may involve gene amplification, increased transcription, increased translation, and other mechanisms. "Mutant encompasses a polypeptide otherwise falling within the sequence identity definition of the IL-B30 as set forth above, but having an amino acid sequence which differs from that of IL-B30 as normally found in nature, whether by way of deletion, substitution, or insertion. This generally includes proteins having significant identity S. with a protein having sequence of SEQ ID NO: 2, and as.

sharing various biological activities, antigenic or 15 immunogenic, with those sequences, and in preferred embodiments contain most of the natural full length disclosed sequences. Full length sequences will typically be preferred, though truncated versions will also be useful, likewise, genes or proteins found from 20 natural sources are typically most desired. Similar concepts apply to different IL-B30 proteins, particularly those found in various warm blooded animals, e.g., mammals and birds. These descriptions are generally meant to encompass all IL-E30 proteins, not limited to the particular primate embodiments specifically discussed.

IL-B30 mutagenesis can also be conducted by making amino acid insertions or deletions. Substitutions, deletions, insertions, or any combinations may be generated to arrive at a final construct. Insertions include amino- or carboxy- terminal fusions. Random mutagenesis can be conducted at a target codon and the expressed mutants can then be screened for the desired activity. Methods for making substitution mutations at predetermined sites ir DNA having a known sequence are well known in the art. by M13 primer mutagenesis or polymerase chain reaction (PCR) techniques. See, e.g., Sambrook, et al. (1989); Ausubel, et al. (1987 and Supplements); and Kunkel, et al. (1987) Methods in Enzvmol. 154:367-381. Preferred embodiments include, 1-fold, 2-fold, 3-fold, 5-fold, 7-fold, etc., preferably conservative substitutions at the nucleotide or amino acid levels. Preferably the substitutions will be away from the conserved cysteines, and often will be in the regions away from the helical structural domains.

Such variants may be useful to produce specific antibodies, and often will share many or all biological properties.

The present invention also provides recombinant proteins, heterologous fusion proteins using segments from these proteins. A heterologous fusion protein is a fusion of proteins or segments which are naturally not normally fused in the same manner. A similar concept applies to heterologous nucleic acid S 15 sequences.

In addition, new constructs may be made from combining similar functional domains from other proteins.

For example, target-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, Cunningham, et al. (1989) Science oo o243:1330-1336; and O'Dowd, et al. (1988) J. Biol. Chem.

263:15985-15992.

The phosphoramidite method described by Beaucage and Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNA fragments. A double :stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence, PCR techniques.

Structural analysis can be applied to this gene, in comparison to the IL-6 family of cytokines. The family includes, IL-6. IL-11, IL-12, G-CSF, LIF, OSM, CNTF, and Ob. Alignment of the human, pig, and mouse IL- E30 sequences with other members of the IL-6 family should allow definition of structural features. In particular, P-sheet and a-helix residues can be determined using, RASMOL program, see Bazan, et al.

(1996) Nature 379:591: Lodi, et al. (1994) Science 263:1762-1766; Sayle and Milner-White (1995) TIBS 20:374- 376; and Gronenberg, et al. (1991) Protein Engineering 4:263-269. Preferred residues for substitutions include the surface exposed residues which would be predicted to interact with receptor. Other residues which should conserve function will be conservative substitutions, particularly at position far from the surface exposed residues.

IV. Functional Variants The blocking of physiological response to may result from the competitive inhibition of binding of the ligand to its receptor.

In vitro assays of the present invention will often use isolated protein, soluble fragments comprising 15 receptor binding segments of these proteins, or fragments attached to solid phase substrates. These assays will also allow for the diagnostic determination of the effects of either binding segment mutations and modifications, or cytokine mutations and modifications, 20 IL-B30 analogs.

This invention also contemplates the use of competitive drug screening assays, where neutralizing antibodies to the cytokine, or receptor binding fragments compete with a test compound.

"Derivatives" of IL-E30 antigens include amino acid S. sequence mutants from naturally occurring forms, glycosylation variants, and covalent or aggregate conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities to groups which are found in IL-B30 amino acid side chains or at the N- or C- termini, by standard means. See, Lundblad and Noyes (1988) Chemical ReaQents for Protein Modification, vols. 1-2, CRC Press, Inc., Boca Raton, FL; Hugli (ed. 1989) Techniques in Protein Chemistry, Academic Press, San Diego, CA; and Wong. (1991) Chemistry of Protein Conjucation and Cross Linking, CRC Press, Boca Raton, FL.

In particular, glycosylation alterations are included, made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing, or in further processing steps. See, e.g., Elbein (1987) Ann. Rev. Biochem. 56:497-534. Also embraced are versions of the peptides with the same primary amino acid sequence which have other minor modifications, including phosphorylated amino acid residues, phosphotyrosine, phosphoserine, or phosphothreonine.

Fusion polypeptides between IL-B30s and other homologous or heterologous proteins are also provided.

Many cytokine receptors or other surface proteins are multimeric, homodimeric entities, and a repeat construct may have various advantages, including lessened susceptibility to proteolytic cleavage. Typical examples 15 are fusions of a reporter.polypeptide, luciferase, with a segment or domain of a protein, a receptorbinding segment, so that the presence or location of the fused ligand may be easily determined. See, Dull, et al., U.S. Patent No. 4,859,609. Other gene fusion S 20 partners include bacterial S-galactosidase, trpE, Protein A, f-lactamase, alpha amylase, alcohol dehydrogenase, yeast alpha mating factor, and detection or purification tags such as a FLAG sequence of His6 sequence. See, Godowski, et al. (1988) Science 241:812-816.

Fusion peptides will typ:cally be made by either recombinant nucleic acid methods cr by synthetic polypeptide methods. Techniques for nucleic acid manipulation and expression are described generally, in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d vois. 1-3, Cold Spring Harbor Laboratory; and Ausubel, et al. (eds. 1993) Current Protocols in Molecular BEiol,, Greene and Wiley, NY.

Techniques for synthesis of polypeptides are described, in Merrifield (1963) J. Amer. Chem. Soc. 85:2149- 2156; Merrifield (1986! Science 232: 341-347; Atherton, et al. (1989) Solid Phase Peptide Snthesis: A Practical Approach, IRL Press. Oxford; and Grant (1992) Synthetic Peptides: A User's Guide, W.H. Freeman, NY. Refolding methods may be applicable to synthetic proteins.

This invention also contemplates the use of derivatives of IL-B30 proteins other than variations in amino acid sequence or glycosylation. Such derivatives may involve covalent or aggregative association with chemical moieties or protein carriers. Covalent or aggregative derivatives will be useful as immunogens, as reagents in immunoassays, or in purification methods such as for affinity purification of binding partners, e.g., other antigens. An IL-B30 can be immobilized by covalent bonding to a solid support such as cyanogen bromideactivated SEPHAROSE, by methods which are well known in the art, or adsorbed onto polyolefin surfaces, with or without glutaraldehyde cross-linking, for use in the assay or purification of anti-IL-B30 antibodies or an 15 alternative binding composition. The IL-B30 proteins can also be labeled with a detectable group, for use in diagnostic assays. Purification of IL-B30 may be effected by an immobilized antibody or complementary binding partner, binding portion of a receptor.

20 A solubilized IL-B30 or fragment of this invention can be used as an immunogen for the production of antisera or antibodies specific for binding. Purified antigen can be used to screen monoclonal antibodies or antigen-binding fragments, encompassing antigen binding fragments of natural antibodies, Fab, Fab', F(ab)2, etc. Purified IL-B30 antigens can also be used as a reagent to detect antibodies generated in response to the presence of elevated levels of the cytokine, which may be diagnostic of an abnormal or specific physiological or disease condition. This invention contemplates antibodies raised against amino acid sequences encoded by nucleotide sequence shown in SEQ ID NO: 1, or fragments of proteins containing it. In particular, this invention contemplates antibodies having binding affinity to or being raised against specific domains, helices A, B, C, or D.

The present invention contemplates the isolation of additional closely related species variants. Southern and Northern blot analysis will establish that similar 4C genetic entities exist in other mammals. It is likely that IL-B30s are widespread in species variants, e.g., rodents, lagomorphs, carnivores, artiodactyla, perissodactyla, and primates.

The invention also provides means to isolate a group of related antigens displaying both distinctness and similarities in structure, expression, and function, Elucidation of many of the physiological effects of the molecules will be greatly accelerated by the isolation and characterization of additional distinct species or polymorphic variants of them. In particular, the present invention provides useful probes for identifying additional homologous genetic entities in different species.

The isolated genes will allow transformation of cells lacking expression of an IL-B30, either species types or cells which lack corresponding proteins and exhibit negative background activity. This should allow analysis of the function of IL-B30 in comparison to untransformed control cells.

Dissection of critical structural elements which effect the various physiological functions mediated through these antigens is possible using standard techniques of modern molecular biology, particularly in comparing members of the related class. See, the homolog-scanning mutagenesis technique described in Cunningham, et al. (1989) Science 243:1339-1336; and approaches used in O'Dowd, et al. (1988) J. Biol. Chem.

263:15985-15992; and Lechleiter, et al. (1990) EMBO J.

9:4381-4390.

Intracellular functions would probably involve receptor signaling. However, protein internalization may occur under certain circumstances, and interaction between intracellular components and cytokine may occur.

Specific segments of interaction of IL-B30 with interacting components may be identified by mutagenesis or direct biochemical means, cross-linking or affinity methods. Structural analysis by crystallographic or other physical methods will also be applicable. Further investigation of the mechanism of signal transduction will include study of associated 23 components which may be isolatable by affinity methods or by genetic means, complementation analysis of mutants.

Further study of the expression and control of IL- B30 will be pursued. The controlling elements associated with the antigens should exhibit differential physiological, developmental, tissue specific, or other expression patterns. Upstream or downstream genetic regions, control elements, are of interest.

Structural studies of the IL-B30 antigens will lead to design of new antigens, particularly analogs exhibiting agonist or antagonist properties on the molecule. This can be combined with previously described screening methods to isolate antigens exhibiting desired 15 spectra of activities.

V. Antibodies Antibodies can be raised to various epitopes of the proteins, including species, polymorphic, or 20 allelic variants, and fragments thereof, both in their naturally occurring forms and in their recombinant forms.

Additionally, antibodies can be raised to IL-B30s in either their active forms or in their inactive forms, including native or denatured versions. Anti-idiotypic antibodies are also contemplated.

S: Antibodies, including binding fragments and single chain versions, against predetermined fragments of the antigens can be raised by immunization of animals with conjugates of the fragments with immunogenic proteins.

Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective IL-B30s, or screened for agonistic or antagonistic activity, mediated through a receptor. Antibodies may be agonistic or antagonistic, by sterically blocking binding to a receptor. These monoclonal antibodies will usually bind with at least a KD of about 1 mM, more usually at least about 300 typically at least about 100 pM, more typically at least about 30 M, preferably at least about 10 pM, and more preferably at least about 3 9M or better.

The antibodies of this invention can also be useful in diagnostic applications. As capture or nonneutralizing antibodies, they can be screened for ability to bind to the antigens without inhibiting binding to a receptor. As neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying IL-B30 protein or its receptors. See, Chan (ed. 1987) Immunolo v: A Practical Guide, Academic Press, Orlando, FL; Price and Newman (eds. 1991) Principles and Practice of Immunoassay, Stockton Press, and Ngo (ed. 1988) Nonisotopic Immunoassay, Plenum Press, N.Y. Cross absorptions or other tests will identify antibodies which exhibit various spectra of specificities, unique or shared species specificities.

Further, the antibodies, including antigen binding fragments, of this invention can be potent antagonists that bind to the antigen and inhibit functional binding, to a receptor which may elicit a biological response. They also can be useful as non-neutralizing a antibodies and can be coupled to toxins or radionuclides so that when the antibody binds to antigen, a cell expressing it, on its surface, is killed. Further, these antibodies can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.

Antigen fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined polypeptides to be used as immunogens. An antigen and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology, Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962) Specificitv of Seroloaical Reactions, Dover Publications, New York; Williams, et al.

(1967) Methods in Immunologv and Immunochemistry, vol. 1, Academic Press, New York; and Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press, NY, for descriptions of methods of preparing polyclonal antisera.

In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, Stites, et al. (eds.) Basic and Clinical Immunology (4th Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d Academic Press, New York; and particularly in Kohler and Milstein (1975) in Nature 256:495-497, which discusses one method of generating monoclonal antibodies.

Other suitable techniques involve in vitro exposure 15 of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors. See, Huse, et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 20 246:1275-1281; and Ward, et al. (1989) Nature 341:544o546. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567; Moore, et al., U.S. Patent No.

4,642,334; and Queen, et al. (1989) Proc. Nat'l Acad.

Sci. USA 86:10029-10033.

The antibodies of this invention can also be used for affinity chromatography in isolating the protein.

Columns can be prepared where the antibodies are linked to a solid support. See, Wilchek et al. (1984) Meth. Enzvmol. 104:3-55.

Antibodies raised against each IL-B30 will also be useful to raise anti-idiotypic antibodies. These will be useful in detecting or diagnosing various immunological conditions related to expression of the respective antigens.

VI. Nucleic Acids The described peptide sequences and the related reagents are useful in detecting, isolating, or identifying a DNA clone encoding IL-B30, from a natural source. Typically, it will be useful in 15 isolating a gene from mammal, and similar procedures will be applied to isolate genes from other species, e.g., warm blooded animals, such as birds and mammals. Cross hybridization will allow isolation of IL-B30 from the same, polymorphic variants, or other species. A 20 number of different approaches will be available to successfully isolate a suitable nucleic acid clone.

The purified protein or defined peptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein can be presented to an immune system to generate monoclonal or polyclonal antibodies. See, Coligan (1991) Current Protocols in Immunolovg Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual, Cold Spring Harbor Press.

For example, the specific binding composition could be used for screening of an expression library made from a cell line which expresses an IL-B30. Screening of intracellular expression can be performed by various staining or immunofluorescence procedures. Binding compositions could be used to affinity purify or sort out cells expressing a surface fusion protein.

The peptide segments can also be used to predict appropriate oligonucleotides to screen a library. The genetic code can be used to select appropriate oligonucleotides useful as probes for screening. See, SEQ ID NO: 1. In combination with polymerase chain reaction (PCR) techniques, synthetic oligonucleotides will be useful in selecting correct clones from a library. Complementary sequences will also be used as probes, primers, or antisense strands. Various fragments should be particularly useful, coupled with anchored vector or poly-A complementary PCR techniques or with complementary DNA of other peptides.

This invention contemplates use of isolated DNA or fragments to encode a biologically active corresponding polypeptide, particularly lacking the portion coding the untranslated 5' portion of the described sequence. In addition, this invention covers isolated or recombinant DNA which encodes a biologically active 15 protein or polypeptide and which is capable of hybridizing under appropriate conditions with the DNA sequences described herein. Said biologically active protein or polypeptide can be an intact antigen, or fragment, and have an amino acid sequence disclosed in, 20 SEQ ID NO: 2, particularly a mature, secreted polypeptide. Further, this invention covers the use of isolated or recombinant DNA, or fragments thereof, which encode proteins which exhibit high identity to a secreted IL-B30. The isolated DNA can have the respective regulatory sequences in the 5' and 3' flanks, e.g., promoters, enhancers, poly-A addition signals, and others. Alternatively, expression may be effected by operably linking a coding segment to a heterologous promoter, by inserzing a promoter upstream from an endogenous gene.

An "isolated" nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a mixed polymer, which is substantially separated from other components which naturally accompany a native sequence, ribosomes, polymerases, and/or flanking genomic sequences from the originating species.

The term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems. A substantially pure molecule includes isolated forms of the molecule.

Generally, the nucleic acid will be in a vector or fragment less than about 50 kb, usually less than about kb, typically less than about 10 kb, and preferably less than about 6 kb.

An isolated nucleic acid will generally be a homogeneous composition of molecules, but will, in some embodiments, contain minor heterogeneity. This heterogeneity is typically found at the polymer ends or portions not critical to a desired biological function or activity.

A "recombinant" nucleic acid is defined either by its method of production or its structure. In reference to its method of production, a product made by a 15 process, the process is use of recombinant nucleic acid techniques, involving human intervention in the nucleotide sequence, typically selection or production.

Alternatively, it can be a nucleic acid made by generating a sequence comprising fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude products of nature, naturally occurring mutants. Thus, products made by transforming cells with any unnaturally occurring vector is encompassed, as are nucleic acids comprising sequence derived using any synthetic oligonucleotide process.

Such is often done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site.

Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly available natural forms. Restriction enzyme recognition sites are often the target of such artificial manipulations, but other site specific targets, promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design. A similar concept is intended for a recombinant, fusion, 4C polypeptide. Specifically included are synthetic nucleic acids which, by genetic code redundancy, encode polypeptides similar to fragments of these antigens, and fusions of sequences from various different species or polymorphic variants.

A significant "fragment" in a nucleic acid context is a contiguous segment of at least about 17 nucleotides, generally at least about 22 nucleotides, ordinarily at least about 29 nucleotides, more often at least about nucleotides, typically at least about 41 nucleotides, usually at least about 47 nucleotides, preferably at least about 55 nucleotides, and in particularly preferred embodiments will be at least about 60 or more nucleotides, 67, 73, 81, 89, 95, etc.

A DNA which codes for an IL-B30 protein will be particularly useful to identify genes, mRNA, and cDNA species which code for related or similar proteins, as well as DNAs which code for homologous proteins from **too: different species. There will be homologs in other species, including primates, rodents, canines, felines, and birds. Various IL-B30 proteins should be homologous and are encompassed herein. However, even proteins that have a more distant evolutionary relationship to the antigen can readily be isolated under appropriate conditions using these sequences if they are sufficiently homologous. Primate IL-B30 proteins are of particular interest.

Recombinant clones derived from the genomic sequences, containing introns, will be useful for transgenic studies, including, transgenic cells and organisms, and for gene therapy. See, Goodnow (1992) "Transgenic Arimals" in Roitt Encyclopedia of Immunology, Academic Press, San Diego, pp. 1502-1504; Travis (1992) Science 256:1392-1394; Kuhn, et a. .(1991) Science 254:707-710; Capecchi (1989) Science 244:1288; Robertson (1967)(ed.) Teratocarcinomas and Embryonic Stem Cells: A Practical ApProach, IRL Press, Oxford; and Rosenberg (1992) Clinical Oncolou 10:180-199.

Substantial homology, identity, in the nucleic acid sequence comparison context means either that the segments, or the-r complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about of the nucleotides, generally at least about 58%, ordinarily at least about 65%, often at least about 71%, typically at least about 77%, usually at least about preferably at least about 95 to 98% or more, and in particular embodiments, as high as about 99% or more of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand, or its complement, typically using a sequence of IL-B30, in SEQ ID NO: 1. Typically, selective hybridization will occur when there is at least about 55% identity over a stretch of at least about 30 nucleotides, preferably at least about See.

oo.. 15 over a stretch of about 25 nucleotides, and most S; preferably at least about 90% over about 20 nucleotides.

See, Kanehisa (1984) Nuc. Acids Res. 12:203-213. The length of identity comparison, as described, may be over longer stretches, and in certain embodiments will be over 20 a stretch of at least about 17 nucleotides, usually at S" least about 28 nucleotides, typically at least about nucleotides, and preferably at least about 75 to 100 or more nucleotides.

Stringent conditions, in referring to homology in the hybridization context, will be stringent combined S. conditions of salt, temperature, organic solvents, and other parameters, typically those controlled in hybridization reactions. Stringent temperature conditions will usually include temperatures in excess of about 300 C, usually in excess of about 370 C, typically in excess of about 550 C, preferably in excess of about 700 C. Stringent salt conditions will ordinarily be less than about 1000 mM, usually less than about 400 mM, typically less than about 250 mM, preferably less than about 150 mM, including about 100, 50, or even 20 mM.

However, the combination of parameters is much more important than the measure of any single parameter. See, Wetmur and Davidson (1968) J. Mol. Biol. 31:349- 370. Hybridization under stringent conditions should give a background of at least 2-fold over background, preferably at least 3-5 or more.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.

The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

Optical alignment of sequences for comparison can be conducted, by the local homology algorithm of Smith 15 and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity .9 method of Pearson and Lipman (1988) Proc. Nat'l Acad.

Sci. USA 85:2444, by computerized implementations of 20 these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the 99 Wisconsin Genetics Software Package, Genetics Computer (roup, 575 Science Dr., Madison, WI), or by visual inspection (see generally Ausubel et al., supra).

.9 9. One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of 9. related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle (1987) J. Mol. Evol. 35:351-360. The method used is similar to the method described by Higgins and Sharp (1989) C7.IOS 5:151-153. The program can align ip to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a 32 simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight default gap length weight and weighted end gaps.

Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described 15 Altschul, et al. (1990) J. Mol. Biol. 215:403-410.

Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http:www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs 20 (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neiahborhood word score threshold (Altschul, et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased.

Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one cr more negative-scoring residue alignments; or the end of either sequence is reached.

The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength of 11, the ELOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Nat'! Acad. S USA 89:10915) alignments of expectation of 10, M=5, N=4, and a comparison of both strands.

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, Karlin and Altschul (1993) Proc. Nat'l Acad. Sci.

USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than 15 about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

A further indication that two nucleic acid sequences of polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is 20 immunologically cross reactive with the polypeptide *encoded by the second nucleic acid, as described below.

Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions.

Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions, as described below.

from other mammalian species can be cloned and isolated by cross-species hybridization of closely related species. Homology may be relatively low between distantly related species, and thus hybridization of relatively closely related species is advisable.

Alternatively, preparation of an antibody preparation which exhibits less species specificity may be useful in expression cloning approaches.

VII. Making IL-B30; Mimetics DNA which encodes the IL-B30 or fragments thereof can be obtained by chemical synthesis, screening cDNA libraries, or screening genomic libraries prepared from a wide variety of cell lines or tissue samples. See, e.g., Okayama and Berg (1982) Mol. Cell. Biol. 2:161-170; Gubler and Hoffman (1983) Gene 25:263-269; and Glover (ed. 1984) DNA Cloning: A Practical Approach, IRL Press, Oxford. Alternatively, the sequences provided herein provide useful PCR primers or allow synthetic or other preparation of suitable genes encoding an including naturally occurring embodiments.

This DNA can be expressed in a wide variety of host cells for the synthesis of a full-length IL-B30 or fragments which can in turn, be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified molecules; S 15 and for structure/function studies.

Vectors, as used herein, comprise plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles which enable the integration of DNA fragments into the genome of the host. See, Pouwels, et al.

20 (1985 and Supplements) Clonino Vectors: A Laboratory Manual, Elsevier, and Rodriguez, et al.

(1988)(eds.) Vectors: A Survey of Molecular Cloning Vectors and Their Uses., Buttersworth, Boston, MA.

For purposes of this invention, DNA sequences are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a preprotein or participates in directing the polypeptide to the cell membrane or in secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to a coding sequence if it is positioned to permit translation. Usually, operably C2 linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linKed but still bind to operator sequences that in turn control expression. See, Rodriguez, et al., Chapter 10, pp. 205-236; Balbas and Bolivar (1990) Methods in Enzynolocv 185:14-37; and Ausubel, et al. (1993) Current Protocols in Molecular Biology, Greene and Wiley, NY.

Representative examples of suitable expression vectors include pCDNAl; pCD, see Okayama, et al. (1985) Mol. Cell Biol. 5:1136-1142; pMClneo Poly-A, see Thomas, et al. (1987) Cell 51:503-512; and a baculovirus vector such as pAC 373 or pAC 610. See, Miller (1988) Ann. Rev. Microbiol. 42:177-199.

It will often be desired to express an polypeptide in a system which provides a specific or defined glycosylation pattern. See, Luckow and Summers (1988) Bio/Technology 6:47-55; and Kaufman (1990) Meth. Enzymol. 185:487-511.

The IL-B30, or a fragment thereof, may be engineered 15 to be phosphatidyl inositol (PI) linked to a cell membrane, but can be removed from membranes by treatment with a phosphatidyl inositol cleaving enzyme, e.g., phosphatidyl inositol phospholipase-C. This releases the antigen in a biologically active form, and allows 20 purification by standard procedures of protein chemistry.

See, Low (1989) Biochim. Biophvs. Acta 988:427-454; Tse, et al. (1985) Science 230:1003-1008; and Brunner, et al. (1991) J. Cell Biol. 114:1275-1283.

Now that the IL-B30 has been characterized, fragments or derivatives thereof can be prepared by conventional processes for synthesizing peptides. These include processes such as are described in Stewart and Young (1984) Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, IL; Bodanszky and Bodanszky (1984) The Practice of Peptide Synthesis, Springer- Verlag, New York; Bodanszky (1984) The Principles of Peptide Synthesis, Springer-Verlag, New York; and Villafranca (ed. 1991) Techniques in Protein Chemistry II, Academic Press, San Diego, Ca.

VIII.Uses The present invention provides reagents which will find use in diagnostic applications as described elsewhere herein, in IL-B30 mediated conditions, or below in the description of kits for diagnosis. The gene may be useful in forensic sciences, to distinguish rodent from human, or as a marker to distinguish between different cells exhibiting differential expression or modification patterns.

This invention also provides reagents with significant commercial and/or therapeutic potential. The (naturally occurring or recombinant), fragments thereof, and antibodies thereto, along with compounds identified as having binding affinity to IL-B30, should be useful as reagents for teaching techniques of molecular biology, immunology, or physiology.

Appropriate kits may be prepared with the reagents, e.g., in practical laboratory exercises in production or use of proteins, antibodies, cloning methods, histology, etc.

The reagents will also be useful in the treatment of conditions associated with abnormal physiology or development, including inflammatory conditions. They may be useful in vitro tests for presence or absence of 20 interacting components, which may correlate with success of particular treatment strategies. In particular, modulation of physiology of various, hematopoietic i or lymphoid, cells will be achieved by appropriate methods for treatment using the compositions provided herein. See, Thomson (1994; ed.) The Cvtokine Handbook (2d ed.) Academic Press, San Diego; Metcalf and Nicola (1995) The Hematopoietic Colony Stimulating Factors Cambridge University Press; and Aggarwal and Gutterman (1991) Human Cvtokines Blackwell Pub.

For example, a disease or disorder associated with abnormal expression or abnormal signaling by an should be a likely target for an agonist or antagonist.

The new cytokine should play a role in regulation or development of hematopoietic cells, lymphoid cells, which affect immunological responses, inflammation and/or autoimmune disorders. Alternatively, it may affect vascular physiology or development, or neuronal effects.

In particular, the cytokine should mediate, in various contexts, cytokine synthesis by the cells, proliferation, etc. Antagonists of IL-B30, such as mutein variants of a naturally occurring form of or blocking antibodies, may provide a selective and powerful way to block immune responses, in situations as inflammatory or autoimmune responses. See also Samter, et al. (eds.) Immunological Diseases vols. 1 and 2, Little, Brown and Co.

In addition, certain combination compositions would be useful, with other modulators of inflammation.

Such other molecules may include steroids, other versions of IL-6 and/or G-CSF, including species variants, or viral homologs, and their respective antagonists.

Various abnormal conditions are known in each of the cell types shown to produce IL-B30 mRNA by Northern blot S 15 analysis. See Berkow The Merck Manual of Diagnosis and Therapy, Merck Co., Rahway, Thorn, et al.

Harrison's Principles of Internal Medicine, McGraw-Hill, and Weatherall, et al. (eds.) Oxford Textbook of Medicine, Oxford University Press, Oxford. Many other 20 medical conditions and diseases involve activation by macrophages or monocytes, and many of these will be responsive to treatment by an agonist or antagonist S. provided herein. See, Stites and Terr (eds.; 1991) S. Basic and Clinical Immunolovg Appleton and Lange, Norwalk, Connecticut; and Samter, et al. (eds.) immunoloqical Diseases Little, Brown and Co. These problems should be susceptible to prevention or treatment using compositions provided herein. The pancreatic islet localization suggests a possible relevance to diabetes.

IL-B30, antagonists, antibodies, etc., can be purified and then administered to a patient, veterinary or human. These reagents can be combined for therapeutic use with additional active or inert ingredients, in conventional pharmaceutically acceptable carriers or diluents, immunogenic adjuvants, along with physiologically innocuous stabilizers, excipients, or preservatives. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized 4C aqueous preparations. This invention also contemplates use of antibodies or binding fragments thereof, including forms which are not complement binding.

Drug screening using IL-B30 or fragments thereof can be performed to identify compounds having binding affinity to or other relevant biological effects on ILfunctions, including isolation of associated components. Subsequent biological assays can then be utilized to determine if the compound has intrinsic stimulating activity and is therefore a blocker or antagonist in that it blocks the activity of the cytokine. Likewise, a compound having intrinsic stimulating activity can activate the signal pathway and is thus an agonist in that it simulates the activity of This invention further contemplates the 15 therapeutic use of blocking antibodies to IL-B30 as antagonists and of stimulatory antibodies as agonists.

This approach should be particularly useful with other species variants.

The quantities of reagents necessary for effective 20 therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents.

Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, in Gilman, et al. (eds. 1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn. Methods for administration are discussed therein and below, for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others. Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, in the Merck Index, Merck Co., Rahway, New Jersey. Dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10 pM concentrations, usually less than about 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier. Slow release formulations, or a slow release apparatus will often be utilized for continuous or long term administration.

See, Langer (1990) Science 249:1527-1533.

fragments thereof, and antibodies to it or its fragments, antagonists, and agonists, may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration.

15 Therapeutic formulations may be administered in many conventional dosage formulations. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.

Formulations typically comprise at least one active 20 ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, topical, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, Gilman, et al. (eds. 1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn.; Avis, et al. (eds. 1993) Pharmaceutical Dosage Forms: Parenteral Medications, Dekker, New York; Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Tablets, Dekker, New York; and Lieberman, et al.

(eds. 1990) Pharmaceutical Dosage Forms: Disperse Systems, Dekker, New York. The therapy of this invention may be combined with or used in association with other agents, other cytokines, including IL-6 or G-CSF, or their respective antagonists.

Both naturally occurring and recombinant forms of the IL-B30s of this invention are particularly useful in kits and assay methods which are capable of screening compounds for binding activity to the proteins. Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of compounds in a short period. See, e.g., Fodor, et al. (1991) Science 251:767-773, which describes means for testing of binding affinity by a plurality of defined polymers synthesized on a solid substrate. The development of suitable assays can be greatly facilitated .:by the availability of large amounts of purified, soluble 15 IL-B30 as provided by this invention.

Other methods can be used to determine the critical residues in IL-B30-IL-B30 receptor interactions.

Mutational analysis can be performed, see Somoza, et al. (1993) J. Exptl. Med. 178:549-558, to determine 20 specific residues critical in the interaction and/or r signaling. PHD (Rost and Sander (1994) Proteins 19:55- 72) and DSC (King and Sternberg (1996) Protein Sci.

5:2298-2310) can provide secondary structure predictions of a-helix P-strand or coil Helices A and D are most important in receptor interaction, with the D helix being the more important region. Helix A would run in the human fror. about pro(7) to his(27), while helix D would run from about trp(135) to gly(162). Surface exposed residues would affect receptor binding, while embedded residues would affect general structure.

Predicted residues of particular importance would likely correspond to arg(146), ser(147), gln(149), ala(150), ala(153), val(154), ala(156), arg(157), ala(160), and his(161).

For example, antagonists can normally be found once the antigen has been structurally defined, by tertiary structure data. Testing of potential interacting analogs is now possible upon the development of highly automated assay methods using a purified IL- .4 B30. In particular, new agonists and antagonists will be 41 discovered by using screening techniques described herein. Of particular importance are compounds found to have a combined binding affinity for a spectrum of molecules, compounds which can serve as antagonists for species variants of One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant DNA molecules expressing an IL-B30. Cells may be isolated which express an IL-B30 in isolation from other molecules. Such cells, either in viable or fixed form, can be used for standard binding partner binding assays. See also, Parce, et al. (1989) Science 246:243- 247; and Owicki, et al. (1990) Proc. Nat'l Acad. Sci. USA 87:4007-4011, which describe sensitive methods to detect 15 cellular responses.

Another technique for drug screening involves an I: approach which provides high throughput screening for compounds having suitable binding affinity to an and is described in detail in Geysen, European Patent 20 Application 84/03564, published on September 13, 1984.

[First, large numbers of different small peptide test compounds are synthesized on a solid substrate, e.g., plastic pins or some other appropriate surface, see Fodor, et al. (1991). Then all the pins are reacted with solubilized, unpurified or solubilized, purified and washed. The next step involves detecting bound IL- Rational drug design may also be based upon structural studies of the molecular shapes of the and other effectors or analogs. Effectors may be other proteins which mediate other functions in response to binding, or other proteins which normally interact with a receptor. One means for determining which sites interact with specific other proteins is a physical structure determination, x-ray crystallography or 2 dimensional NMR techniques. These will provide guidance as to which amino acid residues form molecular contact regions, as modeled, against other cytokine-receptor models. For a.detailed description of protein structural determination, see, 42 Blundell and Johnson (1976) Protein Crystallography, Academic Press, New York.

IX. Kits This invention also contemplates use of proteins, fragments thereof, peptides, and their fusion products in a variety of diagnostic kits and methods for detecting the presence of another IL-B30 or binding partner. Typically the kit will have a compartment containing either a defined IL-B30 peptide or gene segment or a reagent which recognizes one or the other, IL-B30 fragments or antibodies.

A kit for determining the binding affinity of a test compound to an IL-B30 would typically comprise a test 15 compound;,a labeled compound, for example a binding partner or antibody having known binding affinity for IL- B30; a source of IL-B30 (naturally occurring or recombinant); and a means for separating bound from free labeled compound, such as a solid phase for immobilizing 20 the molecule. Once compounds are screened, those having suitable binding affinity to the antigen can be evaluated in suitable biological assays, as are well known in the art, to determine whether they act as agonists or antagonists to the IL-B30 signaling pathway. The availability of recombinant IL-B30 polypeptides also provide well defined standards for calibrating such assays.

A preferred kit for determining the concentration of, an IL-B30 in a sample would typically comprise a labeled compound, binding partner or antibody, having known binding affinity for the antigen, a source of cytokine (naturally occurring or recombinant) and a means for separatina the bound from free labeled compound, a solid phase for immobilizing the IL- B30. Compartments containing reagents, and instructions, will normally be provided.

Antibodies, including antigen binding fragments, specific for the IL-B30 or fragments are useful in diagnostic applications to detect the presence of elevated levels of IL-B30 and/or its fragments. Such diagnostic assays can employ lysates, live cells, fixed cells, immunofluorescence, cell cultures, body fluids, and further can involve the detection of antigens related to the antigen in serum, or the like. Diagnostic assays may be homogeneous (without a separation step between free reagent and antigen-binding partner complex) or heterogeneous (with a separation step). Various commercial assays exist, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), enzyme-multiplied immunoassay technique (EMIT), substrate-labeled fluorescent immunoassay (SLFIA), and the like. See, Van Vunakis, et al. (1980) Meth Enzvmol. 70:1-525; Harlow and 15 Lane (1980) Antibodies: A Laboratory Manual, CSH Press, NY; and Coligan, et al. (eds. 1993) Current Protocols in Immunoloyv, Greene and Wiley, NY.

Anti-idiotypic antibodies may have similar use to diagnose presence of antibodies against an IL-B30, as 20 such may be diagnostic of various abnormal states. For 2* example, overproduction of IL-B30 may result in production of various immunological reactions which may be diagnostic of abnormal physiological states, particularly in proliferative cell conditions such as cancer or abnormal activation or differentiation.

.Moreover, the distribution pattern available provides information that the cytokine is expressed in pancreatic islets, suggesting the possibility that the cytokine may be involved in function of that organ, in a diabetes relevant medical condition.

Frequently, the reagents for diagnostic assays are supplied in kits, so as to optimize the sensitivity of the assay. For the subject invention, depending upon the nature of the assay, the protocol, and the label, either labeled or unlabeled antibody or binding partner, or labeled IL-B30 is provided. This is usually in conjunction with other additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like.

4C Preferably, the kit will also contain instructions for proper use and disposal of the contents after use.

Typically the kit has compartments for each useful reagent. Desirably, the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium providing appropriate concentrations of reagents for performing the assay.

Many of the aforementioned constituents of the drug screening and the diagnostic assays may be used without modification or may be modified in a variety of ways.

For example, labeling may be achieved by covalently or non-covalently joining a moiety which directly or indirectly provides a detectable signal. In any of these assays, the binding partner, test compound, IL-B30, or antibodies thereto can be labeled either directly or indirectly. Possibilities for direct labeling include label groups: radiolabels such as 125I, enzymes (U.S.

at. No. 3,645,090) such as peroxidase and alkaline phosphatase, and fluorescent labels Pat. No.

3,940,475) capable of monitoring the change in 20 fluorescence intensity, wavelength shift, or fluorescence polarization. Possibilities for indirect labeling include biotinylation of one constituent followed by binding to avidin coupled to one of the above label groups.

There are also numerous methods of separating the bound from the free IL-B30, or alternatively the bound from the free test compound. The IL-B30 can be immobilized on various matrixes followed by washing.

Suitable matrixes include plastic such as an ELISA plate, filters, and beads. See. Coligan, et al. (eds.

1993) Current Protoccl in in~munolocv. Vol. 1, Chapter 2, Greene and Wiley, rZ. Other suitable separation techniques include, withot limitation, the fluorescein antibody magnetizable particle method described in Rattle, et al. (1964) Cli.. Chem. 30:1457-1461, and the double antibody magnetic particle separation as described in U.S. Pat. No. 4.659.678.

Methods for linking proteins or their fragments to the various labels have been extensively reported in the literature and do not require detailed discussion here.

Many of the techniques involve the use of activated carboxyl groups either through the use of carbodiimide or active esters to form peptide bonds, the formation of thioethers by reaction of a mercapto group with an activated halogen such as chloroacetyl, or an activated olefin such as maleimide, for linkage, or the like.

Fusion proteins will also find use in these applications.

Another diagnostic aspect of this invention involves use of oligonucleotide or polynucleotide sequences taken from the sequence of an IL-B30. These sequences can be used as probes for detecting levels of the IL-B30 message in samples from patients suspected of having an abnormal condition, inflammatory or autoimmune. Since the cytokine may be a marker or mediator for activation, it 15 may be useful to determine the numbers of activated cells to determine, when additional therapy may be called for, in a preventative fashion before the effects become and progress to significance. The preparation of both RNA and DNA nucleotide sequences, the labeling of 20 the sequences, and the preferred size of the sequences has received ample description and discussion in the literature. See, Langer-Safer, et al. (1982) Proc.

Nat'1. Acad. Sci. 79:4381-4385; Caskey (1987) Science S. 236:962-967; and Wilchek et al. (1988) Anal. Biochem.

171:1-32.

Diagnostic kits which also test for the qualitative or quantitative expression of other molecules are also contemplated. Diagnosis or prognosis may depend on the combination of multiple indications used as markers.

Thus, kits may test for combinations of markers. See, Viallet, et al. (1989) Progress in Growth Factor Res. 1:89-97. Other kits may be used to evaluate other cell subsets.

X. Isolating a IL-E30 Receptor Having isolated a ligand of a specific ligandreceptor interaction, methods exist for isolating the receptor. See, Gearing, et al. (1989) EMBO J. 8:3667- 3676. For example, means to label the IL-B30 cytokine without interfering with the binding to its receptor can be determined. For example, an affinity label can be fused to either the amino- or carboxyl-terminus of the ligand. Such label may be a FLAG epitope tag, or, e.g., an Ig or Fc domain. An expression library can be screened for specific binding of the cytokine, by cell sorting, or other screening to detect subpopulations which express such a binding component. See, Ho, et al. (1993) Proc. Nat'l Acad. Sci. USA 90:11267-11271; and Liu, et al. (1994) J. Immunol. 152:1821-29.

Alternatively, a panning method may be used. See, e.g., Seed and Aruffo (1987) Proc. Nat'l Acad. Sci. USA 84:3365-3369.

Protein cross-linking techniques with label can be applied to isolate binding partners of the S 15 cytokine. This would allow identification of proteins which specifically interact with the cytokine, in a ligand-receptor like manner.

Early experiments will be performed to determine whether the known IL-6 or G-CSF receptor components are 20 involved in response(s) to IL-B30. It is also quite possible that these functional receptor complexes may share many or all components with an IL-B30 receptor complex, either a specific receptor subunit or an accessory receptor subunit.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

EXAMPLES

I. General Methods Many of the standard methods below are described or referenced, in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY; Sambrook, et 4C al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.) Vols. 1-3, CSH Press, NY; Ausubel, et al., Biology Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology Wiley/Greene, NY; Innis, et al. (eds.

1990) PCR Protocols: A Guide to Methods and Applications Academic Press, NY. Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, Ausubel, et al.

(1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification," Methods in Enzymolocy vol. 182, and other volumes in this series; Coligan, et al. (1995 and supplements) Current Protocols in Protein Science John Wiley and Sons, New York, NY; P. Matsudaira (ed.

15 1993) A Practical Guide to Protein and Peptide Purification for Microsequencing, Academic Press, San Diego, CA; and manufacturer's literature on use of protein purification products, Pharmacia, Piscataway, NJ, or Bio-Rad, Richmond, CA. Combination 20 with recombinant techniques allow fusion to appropriate segments (epitope tags), to a FLAG sequence or an equivalent which can be fused, via a proteaseremovable sequence. See, Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, NY; and Crowe, et al. (1992) QIAex-ress: The High Level Expression Protein Purification System QUIAGEN, Inc., Chatsworth, CA.

Standard immunological techniques are described, in Hertzenberg, et al. (eds. 1996) Weir's Handbook of Experimental Immunology vols. 1-4, Blackwell Science; Coligan (1991) Current Protocols in Immunology Wiley/Greene, NY; and Methods in Enzymoloav vols. 70, 73, 74, 84, 92, 93, 108, 116, 121, 132, 150, 162, and 163.

Cytokine assays are described, in Thomson (ed.

1994) The Cvtokine Handbook (2d ed.) Academic Press, San Diego; Metcalf and Nicola (1995) The Hematopoietic Colony Stimulating Factors Cambridge University Press; and Aggarwal and Gutterman (1991) Human Cvtokines Blackwell Pub.

Assays for vascular biological activities are well known in the art. They will cover angiogenic and angiostatic activities in tumor, or other tissues, e.g., arterial smooth muscle proliferation (see, Koyoma, et al. (1996) Cell 87:1069-1078), monocyte adhesion to vascular epithelium (see McEvoy, et al. (1997) J. Exp.

Med. 185:2069-2077), etc. See also Ross (1993) Nature 362:801-809; Rekhter and Gordon (1995) Am. J. Pathol.

147:668-677; Thyberg, et al. (1990) Atherosclerosis 10:966-990; and Gumbiner (1996) Cell 84:345-357.

Assays for neural cell biological activities are described, in Wouterlood (ed. 1995) Neuroscience Protocols modules 10, Elsevier; Methods in Neurosciences Academic Press; and Neuromethods Humana Press, Totowa, NJ. Methodology of developmental systems is described, in Meisami Handbook of Human Growth and Developmental Biolooy CRC Press; and Chrispeels (ed.) S 20 Molecular Techniues and Approaches in Developmental 0Biology Interscience.

FACS analyses are described in Melamed, et al.

(1990) Flow Cytometry and Sorting Wiley-Liss, Inc., New York, NY; Shapiro (1988) Practical Flow Cvtometrv Liss, 00 25 New York, NY; and Robinson, et al. (1993) Handbook of Flow Cvtometry Methods Wiley-Liss, New York, NY.

0: 00 II. Cloning of Human The sequence of the gene is provided in Table 1.

The sequence is derived from a cDNA library made from melanocyte, fetal heart, and pregnant uterus. It is also found from a cDNA library sequence derived from a pancreatic islet. These sequences allow preparation of PCR primers, or probes, to determine cellular distribution of the gene. The sequences allow isolation of genomic DNA which encode the message.

Using the probe or PCR primers, various tissues or cell types are probed to determine cellular distribution.

PCR products are cloned using, a TA cloning kit (Invitrogen). The resulting cDNA plasmids are sequenced from both termini on an automated sequencer (Applied Biosystems).

III. Cellular Expression of An appropriate probe or primers specific for cDNA encoding primate IL-B30 are prepared. Typically, the probe is labeled, by random priming. The expression is probably in the cell types described, and perhaps also in pancreatic islets. Southern Analysis: DNA (5 gg) from a primary amplified cDNA library was digested with appropriate restriction enzymes to release the inserts, run on a 1% S. agarose gel and transferred to a nylon membrane (Schleicher and Schuell, Keene, NH).

15 Samples for human mRNA isolation include: peripheral blood mononuclear cells (monocytes, T cells, NK cells, granulocytes, B cells), resting (T100); peripheral blood mononuclear cells, activated with anti-CD3 for 2, 6, 12 h pooled (T101); T cell, THO clone Mot 72, resting (T102); 20 T cell, THO clone Mot 72, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T103); T cell, THO clone Mot 72, anergic treated with specific peptide for 2, 7, 12 h pooled (T104); T cell, TH1 clone HY06, resting 0(T107); T cell, TH1 clone HY06, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T108); T cell, TH1 clone HY06, anergic treated with specific peptide for 2, 6, 12 h pooled (7109); T cell, TH2 clone HY935, resting (T110); T cell, TH2 clone HY935, activated with anti-CD28 and anti-CD3 for 2, 12 h pooled (T1ll); T cell tumor lines Jurkat and Hut78, resting (T117); T cell clones, pooled AD130.2, Tc7E3.12, Tc783.13, Tc783.58, Tc782.69, resting (T118); T cell random y5 T cell clones, resting (T119); CD28- T cell clone; Splenocytes, resting (B100); Splenocytes, activated with anti-CD40 and IL-4 (B101); B cell EBV lines pooled WT49, RSB, JY, CVIR, 721.221, RM3, HSY, resting (E102); B cell line JY, activated with PMA and ionomycin for 1. 6 h pooled (B103); NK 20 clones pooled, resting (K100); NK 20 clones pooled, activated with PMA and ionomycin for 6 h (K101); NKL clone, derived from peripheral blood of LGL leukemia patient, IL-2 treated (K106) hexnatopoietic precursor line TFl, activated with PMA and ionomycin for 1, 6 h pooled (CiQO) U937 premonocytic line, resting (M1QO) U937 premonocytic line, activated with PMA and ionomycin for 1, 6 h pooled (MiOl); elutriated monocytes, activated with LPS, IFNy, anti-IL-lO for 1, 2, 6, 12, 24 h pooled (M102); elutriated rnonocytes, activated with LPS, IFN'Y, for 1, 2, 6, 12, 24 h pooled (M103) elutriated monocytes, activated with LPS, IFN-y, anti-IL-lO for 4, 16 h pooled (M1O6); elutriated monocytes, activated with LPS, IFNy, IL-10 for 4, 16 h pooled (M107) elutriated monocytes, activated LPS for 1 h (M108); elutriated monocytes, activated LPS for 6 h (M109) DC 70% CDlai, from CD34+ GM-CSF, TNFcx 12 days, resting (Dl01); DC 15 CDla+, from CD34+ GM-CSF, TNFa 12 days, activated with PMA% and ionornycin for 1 hr MD102); DC 70% CDla+, from CD34+ GM-CSF, TNF~x 12 days, activated with PMA and ionomycin for 6 hr (D103); DC 95% CDla-, from CD34+ GM- CSF, TNFcX 12 days FACS sorted, activated with PMA and 20 ionomycin for 1, 6 h pooled MD104); DC 95% CDl4+, ex CD34+ GM-CSF, TNFQX 12 days FACS sorted, activated with PMA arnd ionomycin 1, 6 hr pooled (D105); DC CDla+ CD86+, :from CD34+ GM-CSF, TNFQX 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D106); DC from monocytes GM-CSF, IL-4 5 days. resting (D107) DC from monocytes GM-CSF, !L-4 5 days, resting (D1O8) DC from .:monocytes GM-CSF, IL-4 5 days, activated LPS 4, 16 h pooled MD109); DC from monocyzes GM-CSF, IL-4 5 days, activated TNFax, monocyte supe for 4, 16 h pooled (D1O); epithelial cells, unstimulated; epithelial cells, activated; lung fibroblast sarcoma line MC5, activated With PMA and ionomycin for 1, 6 h pooled (C10l); kidney epithelial carcinoma cell line CH-A, activated with PMA and ionomycin for 1, 6 h pooled (C102). Expression of 3 5 IL-B30 transcript was very high in elutriated monocytes, activated with LPS, IFN-y, anti-IL-1O for 4, 16 h pooled (M106); elutriated monocytes, activated with LPS, IFNY, anti-IL-lO for 1, 2, 6, 12, 24 h pooled (M102); elutriated monocytes, activated LPS for 6 h (M109); and elutriated monocytes, activated LPS for 1 h (M108).

Expression was high in DC 95% CDla+, from CD34+ GM-CSF, TNFa 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D104); and NK 20 clones pooled, activated with PMA and ionomycin for 6 h (K101).

Lesser expression was detected in DC 70% CDla+, from CD34+ GM-CSF, TNFa 12 days, activated with PMA and ionomycin for 6 hr (D103); DC 70% CDla+, from CD34+ GM- CSF, TNFa 12 days, activated with PMA and ionomycin for 1 hr (D102); T cell, TH1 clone HY06, anergic treated with specific peptide for 2, 6, 12 h pooled (T109); peripheral blood mononuclear cells, activated with anti-CD3 for 2, 6, 12 h pooled (T101); T cell, THO clone Mot 72, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T103); Splenocytes, activated with anti-CD40 and 15 IL-4 (B101); T cell, THO clone Mot 72, anergic treated with specific peptide for 2, 7, 12 h pooled (T104); Splenocytes, resting (B100); T cell, TH1 clone HY06, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T108); epithelial cells, IL-1P activated; 20 elutriated monocytes, activated with LPS, IFNy, IL-10 for 4, 16 h pooled (M107); and B cell line JY, activated with PMA and ionomycin for 1, 6 h pooled (B103).

Detectable expression was observed in DC from monocytes GM-CSF, IL-4 5 days, activated LPS 4, 16 h pooled (D109); T cell, THO clone Mot 72, resting (T102); peripheral blood mononuclear cells (monocytes, T cells, NK cells, granulocytes, B cells), resting (T100);T cells CD4+CD45RO- T cells polarized 27 days in anti-CD28, IL-4, and anti IFN-y, TH2 polarized, activated with anti-CD3 3C and anti-CD28 4 h (T116); T cell clones, pooled AD130.2, Tc783.12, Tc783.13, Tc783.58, Tc782.69, resting (T118); U937 premonocytic line, resting (M100); hematopoietic precursor line TFI, activated with PMA and ionomycin for 1, 6 h pooled (C100); T cell, TH2 clone HY935, activated with anti-CD28 and anti-CD3 for 2, 7, 12 h pooled (T1ll); DC CDla+ CD86, from CD34+ GM-CSF, TNFa 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D106); elutriated monocytes, activated with LPS, IFNy, IL-10 for I, 2, 6, 12, 24 h pooled (M103); DC from 4C monocytes GM-CSF, IL-4 5 days, activated TNFa, monocyte supe for 4, 16 h pooled (D110); DC from monocytes GM-CSF, IL-4 5 days, resting (D108); U937 premonocytic line, activated with PMA and ionomycin for 1, 6 h pooled (M101); T cell random y5 T cell clones, resting (T119); and T cell, TH1 clone HY06, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T108). No signal was detected in the other samples.

In summary, the distribution shows IL-B30 elevated in activated macrophages, suggesting a role in inflammation; activated Thl cells, suggesting a regulation or effector role in T helper subsets, particularly Thl immune responses; and activated dendritic cells, suggesting a role in antigen presentation or germinal center T or B cell interactions 15 with DC.

Samples for mouse mRNA isolation include: resting mouse fibroblastic L cell line (C200); Braf:ER (Braf fusion to estrogen receptor) transfected cells, control (C201); Mell4+ naive T cells from spleen, resting (T209); 20 Mell4+ naive T cells from spleen, stimulated with IFNy, IL-12, and anti IL-4 to polarize to TH1 cells, exposed to IFNy and IL-4 for 6, 12, 24 h, pooled (T210); Mell4+ naive T cells from spleen, stimulated with IL-4 and anti IFNy to polarize to Th2 cells, exposed to IL-4 and anti IFNy for 6, 13, 24 h, pooled (T211); T cells, TH1 polarized (Mell4 bright, CD4+ cells from spleen, polarized for 7 days with IFN-y and anti IL-4; T200); T cells, TH2 polarized (Mell4 bright, CD4+ cells from spleen, polarized for 7 days with IL-4 and anti-IFN-y; T201); T cells, highly TI1 polarized 3x from transgenic Balb/C (see Openshaw. et al. (1995) J. Exp. Med.

182:1357-1367; activated with anti-CD3 for 2, 6, 24 h pooled; T202); T cells, highly TH2 polarized 3x from transgenic Balb/C (activated with anti-CD3 for 2, 6, 24 h pooled (T203); T cells, highly THI polarized 3x from transgenic C57 bl/6 (activated with anti-CD3 for 2, 6, 24 h pooled; T212); T cells, highly TH2 polarized 3x from transgenic C57 bl/6 (activated with anti-CD3 for 2, 6, 24 h pooled; T213); T cells, highly TH1 polarized (naive CD4+ T cells from transgenic Balb/C, polarized 3x with IFNy, IL-12, and anti-IL-4; stimulated with IGIF, IL-12, and anti IL-4 for 6, 12, 24 h, pooled); CD44- CD25+ pre T cells, sorted from thymus (T204); TH1 T cell clone D1.1, resting for 3 weeks after last stimulation with antigen (T205); TH1 T cell clone D1.1, 10 gg/ml ConA stimulated h (T206); TH2 T cell clone CDC35, resting for 3 weeks after last stimulation with antigen (T207); TH2 T cell clone CDC35, 10 gg/ml ConA stimulated 15 h (T208); unstimulated B cell line CH12 (B201); unstimulated mature B cell leukemia cell line A20 (B200); unstimulated large B cells from spleen (B202); B cells from total spleen, LPS activated (B203); metrizamide enriched dendritic cells from spleen, resting (D200); dendritic cells from bone marrow, resting (D201); unstimulated bone marrow derived dendritic cells depleted with anti B220, anti CD3, and anti Class II, cultured in GM-CSF and IL-4 (D202); bone marrow derived dendritic cells depleted with anti B220, anti CD3, and anti Class II, cultured in GM- CSF and IL-4, stimulated with anti CD40 for 1, 5 d, pooled (D203); monocyte cell line RAW 264.7 activated with LPS 4 h (M200); bone-marrow macrophages derived with GM and M-CSF (M201); bone-marrow macrophages derived with GM-CSF, stimulated with LPS, IFNy, and IL-10 for 24 h (M205); bone-marrow macrophages derived with GM-CSF, stimulated with LPS, IFNy, and anti IL-10 for 24 h S" (M206); peritoneal macrophages (M207); macrophage cell line J774, resting (M:2C2 macrophage cell line J774 LPS anti-IL-10 at 0.5, 1, 3, 6, 12 h pooled (M203); macrophage cell line J774 LPS IL-10 at 0.5, 1, 3, 12 h pooled (M204); unstimulated mast cell lines MC-9 and MCP-12 (M208); immortalized endothelial cell line derived from brain microvasc'uar endothelial cells, unstimulated (E200); immortalized endothelial cell line derived from brain microvascular endothelial cells, stimulated overnight with TNF( (E201); immortalized endothelial cell line derived from brain microvascular endothelial cells, stimulated overnight with TNFr (E202) immortalized endothelial cell line derived from brain microvascular endothelial cells, stimulated overnight with TNFa and IL- 54 (E203); total aorta from wt C57 bl/6 mouse; total aorta from 5 month ApoE KO mouse (X207); total aorta from 12 month ApoE KO mouse (X207); wt thymus (0214); total thymus, rag-i (0208); total kidney, rag-i (0209); total kidney, NZ B/W mouse; and total heart, rag-1 (0202).

High signal was detected in the monocyte cell line RAW 264.7 activated with LPS 4 h (M200); T cells, highly TH1 polarized 3x from transgenic C57 bl/6 (activated with anti-CD3 for 2, 6, 24 h pooled; T212); and T cells, highly TH1 polarized (naive CD4+ T cells from transgenic Balb/C, polarized 3x with IFNy, IL-12, and anti-IL-4; stimulated with IGIF, IL-12, and anti IL-4 for 6, 12, 24 h, pooled). Detectable signals were detected in T cells, highly TH1 polari'zed 3x from transgenic Balb/C (see 15 Openshaw, et al. (1995) J. Ex~. Med. 182:1357-1367; activated with anti-CD3 for 2, 6, 24 h pooled; T202); T cells, TH2 polarized (Mell4 bright, CD4+ cells from spleen, polarized for 7 days with IL-4 and anti-IFN-y; T201); T cells, TH1 polarized (Mell4 bright, CD4+ cells 20 from spleen, polarized for 7 days with IFN-y and anti IL- 4; T200); macrophage cell line J774 LPS anti-IL-10 at 1, 3, 6, 12 h pooled (M203); macrophage cell line J774, resting (M202); macrophage cell line J774 LPS IL-10 at 0.5, 1, 3, E. 12 h pooled (M204); immortalized endothelial cell line derived from brain microvascular endothelial cells, stimulated overnight with TNFa (E201); and bone-marrow macrophages derived with GM-CSF, stimulated with LPS, IFNy, and anti :L-10 for 24 h (M206). Other samples showed no signal. The expression in the RAW 264.7 mouse monocyte cell line suggests a natural source for protein.

IV. Chromosome mapping of An isolated cDNA encoding the IL-B30 is used.

Chromosome mapping is a standard technique. See, e.g., BIOS Laboratories (New Haven, CT) and methods for using a mouse somatic cell hybrid panel with PCR. Circumstantial evidence suggests that the mouse IL-B30 gene maps to chromosome V. Purification of IL-B30 Protein Multiple transfected cell lines are screened for one which expresses the cytokine at a high level compared with other cells. Various cell lines are screened and selected for their favorable properties in handling.

Natural IL-B30 can be isolated from natural sources, or by expression from a transformed cell using an appropriate expression vector. Purification of the expressed protein is achieved by standard procedures, or may be combined with engineered means for effective purification at high efficiency from cell lysates or supernatants. FLAG or His6 segments can be used for such purification features. Alternatively, affinity chromatography may be used with specific antibodies, see 15 below.

Protein is produced in coli, insect cell, or mammalian expression systems, as desired.

VI. Isolationiof Homologous IL-B30 Genes 20 The IL-B30 cDNA, or other species counterpart sequence, can be used as a hybridization probe to screen a library from a desired source, a primate cell cDNA library. Many different species can be screened *both for stringency necessary for easy hybridization, and for presence using a probe. Appropriate hybridization conditions will be used to select for clones exhibiting specificity of cross hybridization.

Screening by hybridization using degenerate probes based upon the peptide sequences will also allow isolation of appropriate clones. Alternatively, use of appropriate primers for PCR screening will yield enrichment of appropriate nucleic acid clones.

Similar methods are applicable to isolate either species, polymorphic, or allelic variants. Species variants are isolated using cross-species hybridization techniques based upon isolation of a full length isolate or fragment from one species as a probe.

Alternatively, antibodies raised against human ILwill be used to screen for cells which express cross- 4C reactive proteins from an appropriate, cDNA library. The purified protein or defined peptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, Coligan (1991) Current Protocols in Immunolocr Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press. The resulting antibodies are used for screening, purification, or diagnosis, as described.

VII. Preparation of antibodies specific for Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See,: Coligan (1991) Current Protocols 15 in Immunolooy Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory, Manual Cold Spring Harbor Press.

S..Polyclonal serum, or hybridomas may be prepared. In appropriate situations, the binding reagent is either labeled as described above, e.g4, fluorescence or 20 otherwise, or immobilized to a substrate for panning methods. Immunoselection and related techniques are available to prepare selective reagents, as desired.

VIII. Evaluation of Breadth of Biological Functions Biological activities of IL-B30 were tested based on the sequence and structural homology between IL-B30 and IL-6 and G-CSF. In.ially. assays that had shown biological activities of IL-6 or G-CSF are examined.

A. Effects on proliferation of cells The effect on prcliferation of various cell types are evaluated with various concentrations of cytokine. A dose response analysis is performed, in combinations with the related cytokines G-CSF, etc.

B. Effects on the expression of cell surface molecules on human monocytes Monocytes are purified by negative selection from peripheral blood mononuclear cells of normal healthy donors. Briefly. 3 x 108 ficoll banded mononuclear cells are incubated on ice with a cocktail of monoclonal antibodies (Becton-Dickinson; Mountain View, CA) consisting, of 200 .1 of aCD2 (Leu-5A), 200 .1 of aCD3 (Leu-4), 100 p1 of aCD8 (Leu 2a), 100 p1 of aCD19 (Leu-12 100 1l of cCD20 (Leu-16), 100 .l of aCD56 (Leu-19), 100 .1 of aCD67 (IOM 67; Immunotech, Westbrook, ME), and anti-glycophorin antibody (10F7MN, ATCC, Rockville, MD). Antibody bound cells are washed and then incubated with sheep anti-mouse IgG coupled magnetic beads (Dynal, Oslo, Norway) at a bead to cell ratio of 20:1. Antibody bound cells are separated from monocytes by application of a magnetic field. Subsequently, human monocytes are cultured in Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in the absence or presence of IL-B30, IL-6, G-CSF or 15 combinations.

Analyses of the expression of cell surface molecules can be performed by direct immunofluorescence. For example, 2 x 10 5 purified human monocytes are incubated in phosphate buffered saline (PBS) containing 1% human 20 serum on ice for 20 minutes. Cells are pelleted at 200 x g. Cells are resuspended in 20 ml PE or FITC labeled mAb. Following an additional 20 minute incubation on ice, cells are washed in PBS containing 1% human serum followed by two washes in PBS alone. Cells are fixed in PBS containing 1% paraformaldehyde and analyzed on FACScan flow cytometer (Becton Dickinson; Mountain View, CA). Exemplary mAbs are used, CDllb (anti-macl), CDllc (a gpl50/95), CD14 (Leu-M3), CD54 (Leu 54), (anti-BBl/B7), HLA-DR (L243) from Becton-Dickinson and CD86 (FUN 1; Pharmingen), CD64 (32.2; Medarex), (mAb89; Schering-Plough France).

C. Effects of IL-B30 on cytokine production by human monocytes Human monocytes are isolated as described and cultured in Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in the absence or presence of IL-B30 (1/100 dilution baculovirus expressed material). In addition, monocytes are stimulated with LPS coli 0127:B8 Difco) in the absence or presence of IL-B30 and the concentration of cytokines (IL-1p, IL-6, TNFa, GM-CSF, and IL-10) in the cell culture supernatant determined by ELISA.

For intracytoplasmic staining for cytokines, monocytes are cultured (1 million/ml) in Yssel's medium in the absence or presence of IL-B30 and LPS coli 0127:B8 Difco) and 10 mg/ml Brefeldin A (Epicentre technologies Madison WI) for 12 hrs. Cells are washed in PBS and incubated in 2% formaldehyde/PBS solution for minutes at RT. Subsequently cells are washed, resuspended in permeabilization buffer saponin (Sigma) in PBS/BSA /Azide (1 mM)) and incubated for 20 minutes at RT. Cells (2 x 105) are centrifuged and resuspended in 20 ml directly conjugated anticytokine mAbs diluted 1:10 in permeabilization buffer for 20 minutes at RT. The following antibodies can be used: IL-la-PE (364-3B3-14); IL-6-PE (MQ2-13A5); TNFa-PE (MAbll); GM-CSF-PE (BVD2-21C11); and IL-12-PE (Cll.5.14; Pharmingen San Diego, CA). Subsequently, cells are 20 washed twice in permeabilization buffer and once in .9 PBS/BSA/Azide and analyzed on FACScan flow cytometer (Becton Dickinson; Mountain View, CA) o D. Effects of IL-B30 on proliferation of human peripheral blood mononuclear cells (PBMC) Total PBMC are isolated from buffy coats of normal healthy donors by centrifugation through ficoll-hypaque S* as described (Boy=m, et al.. PBMC are cultured in 200 i1 Yssel's medium (Gemini Bioproducts, Calabasas, CA) 3C containing 1% human AB serum in 96 well plates (Falcon, Becton-Dickinson, NJ) in the absence or presence of IL- Cells are cultured in medium alone or in combination with 100 U/ml IL-2 (R&D Systems) for 120 hours. 3H-Thymidine (0.I mCi) is added during the last six hours of culture and 3H-Thymidine incorporation determined by liquid scintillation counting.

The native, recombinant, and fusion proteins would be tested for agonist and antagonist activity in many other biological assay systems, on T-cells, Bcells, NK, macrophages, dendritic cells, hematopoietic progenitors, etc. Because of the IL-6 and G-CSF structural relationship, assays related to those activities should be analyzed is evaluated for agonist or antagonist activity on transfected cells expressing IL-6 or G-CSF receptor and controls. See, Ho, et al. (1993) Proc. Nat'l Acad. Sci. USA 90, 11267-11271; Ho, et al.

(1995) Mol. Cell. Biol. 15:5043-5053; and Liu, et al.

(1994). J. Immunol. 152:1821-1829.

IL-B30 is evaluated for effect in macrophage/dendritic cell activation and antigen presentation assays, T cell cytokine production and proliferation in response to antigen or allogeneic stimulus. See, de Waal Malefyt et al. (1991) J.

15 Exr. Med. 174:1209-1220; de Waal Malefyt et al. (1991) J.

Exo. Med. 174:915-924; Fiorentino, et al. (1991) J.

Immunol. 147, 3815-3822; Fiorentino, et al. (1991) J_ Immunol. 146:3444-3451; and Groux, et al. (1996) J. Exp.

Med. 184:19-29.

20 IL-B30 will also be evaluated for effects on NK cell %see* stimulation. Assays may be based, on Hsu, et al.

(1992) Internat. Immunol. 4:563-569; and Schwarz, et al.

(1994) J. Immunother. 16:95-104.

B cell growth and differentiation effects will be analyzed, by the methodology described, in Defrance, et al. (1992). J. Exp. Med. 175:671-682; Rousset, et al. (1992) Proc. Nat'l Acad. Sci. USA 89:1890-1893; including IgG2 and IgA2 switch factor assays. Note that, unlike COS7 supernatants, NIH3T3 and COP supernatants apparently do not interfere with human B cell assays.

S Generation and Analysis of Genetically Altered Animals Transgenic mice can be generated by standard methods. Such animals are useful to determine the effects of deletion of the gene, in specific tissues, or completely throughout the organism. Such may provide interesting insight into development of the animal or particular tissues in various stages. Moreover, the 60 effect on various responses to biological stress can be evaluated. See, Hogan, et al. (1995) Manipulating the Mouse Embryo: A Laboratory Manual (2d ed.) Cold Spring Harbor Laboratory Press.

A transgenic mouse has been generated, and while the animal seems to survive birth, it fails to thrive, and typically dies within a few weeks. The construct is based upon an actin promoter within a CMV enhancer, which should lead to broad and high expression. The mice, like IL-6 transgenic mice, are runted. Moreover, they exhibit a bloated abdomen, inflammation of the stomach and intestines, infiltration of cells into the liver, and typically die before day 50. These mice do not breed. A second subset of the transgenic mice have a less severe phenotype, and attempts to breed them are taking place.

The genomic structure for the mouse IL-B30 has been determined. A strategy for the production of knock-out mice has been developed, and constructs have been started.

All references cited herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and indicated to be incorporated by reference in its entirety 25 for all purposes.

Many modifications and variations of this invention can be made without departing from its spirit and scope, S* as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as 60a "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition or further features in various embodiments of the invention.

It is to be understood that a reference herein to a prior art document does not constitute an admission that the document forms part of the common general knowledge in the art in Australia or in any other country.

S*

*g g.SS EDITORIAL NOTE APPLICATION NUMBER 18045/02 The following Sequence Listing pages 1 to 15 are part of the description. The claims pages follow on pages "61" to "67".

1 SEQUENCE LISTING SEQ ID NO: 1 is a primate IL-B30 natural nucleic acid sequence.

SEQ ID NO: 2 is a primate IL-B30 natural amino acid sequence.

SEQ ID NO: 3 is a rodent IL-B30 natural nucleic acid sequence.

SEQ ID NO: 4 is a rodent IL-B30 natural amino acid sequence.

SEQ ID NO: 5 is a pig SEQ ID NO: 6 is bovine G-CSF.

SEQ ID NO: 7 is feline G-CSF.

SEQ ID NO: 8 is human G-CSF.

SEQ ID NO: 9 is mouse G-CSF.

SEQ ID NO: 10 is otter IL-6.

SEQ ID NO: 11 is feline IL-6.

SEQ ID NO: 12 is human IL-6.

SEQ ID NO: 13 is sheep IL-6.

SEQ ID NO: 14 is mouse IL-6.

SEQ ID NO: 15 is chicken MGF.

SEQ ID NO: 16 is KSHV, kaposi's sarcoma herpes virus, a viral IL-6.

GENERAL INFORMATION: APPLICANT: Schering Corporation (ii) TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS (iii) NUMBER OF SEQUENCES: 16 30 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: Schering Corporation STREET:2000 Galloping Hill Road CITY: Kenilworth STATE: New Jersey 35 COUNTRY: USA ZIP: 07033-0530 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk 40 COMPUTER: Power Macintosh 7600/120 OPERATING SYSTEM: Windows SOFTWARE: MS Word (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: FILING DATE: July 24, 1998

CLASSIFICATION:

(vii) PRIOR APPLICATION DATA: APPLICATION NUMBER: US 08/900,905 FILING DATE: 25-JUL-1997 (viii) ATTORNEY/AGENT INFORMATION: NAME: Thampoe, Immac J.

REGISTRATION NUMBER: 36,322 REFERENCE/DOCKET NUMBER: DX0758K1 (ix) TELECOMMUNICATION INFORMATION: TELEPHONE: (908) 298-5061 TELEFAX: (908) 298-5388 INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 570 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 1. .567 (ix) FEATURE: NAME/KEY: mat-peptide LOCATION: 64. .567 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: a a a a.

a a.

a. a.

ATG

25 Met -21

GCT

Ala 30 -5

TGC

Cys

CCA

Pro 40 ACA Thr

GGA

Gly

CTG

Leu

CCT

Pro

CTG

Leu

CTG

Leu -20

CAG

Gln

CAG

Gln

CTA

Leu

AAT

Asn 45

CTC

Leu

ATT

Ile

TOT

Ser

GGC

Gly GGG AGC AGA GCT GTA ATG CTG CTG TTG CTG CTG CCC TGG ACA Gly Ser Arg Ala Val Met Leu Leu Leu

AGA

Arg

CTT

Leu

GGA

Gly

GTT

Val1

GAC

Asp

TAT

Tyr

CTC

Leu

AGO

Ser -15 GTG CCT Val Pro 1 CAG AAG Gln Lys ATG GAT Met Asp CAT ATC His Ile 50 AGT CAG Ser Gin 65 AAG CTG Lys Leu GAT AGO Asp Ser CTO CTG Leu Leu

GGG

Gly

OTC

Leu

CTA

Leu 35

CAG

Gln

TTC

Phe

CTA

Leu

CT

Pro

CAG

Gln 115

GGC

Gly

TGC

Cys 20

AGA

Arg

TGT

Cys

TGC

Cys

GGA

Gly

GTG

Val 100

CT

Pro AGC AGO Ser Ser 5 ACA CTG Thr Leu GAA GAG Giu Glu GGA GAT Gly Asp TTG CAA Leu Gin 70 TOG GAT Ser Asp 85 GOG CAG Ala Gin GAG GGT Giu Gly Leu

OCT

Pro

GC

Ala

GGA

Gly

GGO

Gly

AGG

Arg

ATT

Ile

OTT

Leu

CAC

His Leu

GCC

Ala

TOG

Trp

GAT

Asp

TOT

Cys

ATC

Ile

TTC

Phe

CAT

His

CAC

His 120 Pro

TGG

Trp

AGT

Ser

GAA

Glu

GAC

Asp

CAC

His

ACA

Thr

GCC

Ala 105

TGG

Trp Trp,

ACT

Thr

GCA

Ala

GAG

Glu

CCC

Pro

CAG

Gin

GGG

Gly

TCC

Ser

GAG

Giu Thr

CAG

Gin

CAT

His

ACT

Thr

CAA

Gin

GGT

Gly

GAG

Glu

CTA

Leu

ACT

Thr 48 96 144 192 240 288 336 384 432 480 CAG CAG ATT CCA AGO CTC AGT CCC AGC CAG OCA TGG CAG CGT CTC CTT Gin Gin 125 Ile Pro Ser Leu Pro Ser Gln Pro Gln Arg Leu Leu

CTC

Leu 140

GCC

Ala CGC TTC AAA ATC Arg Phe Lys Ile CGG GTC TTT GCC Arg Val Phe Ala 160 3 CTT CGC AGC CTC CAG GCC TTT GTG GCT GTA GCC Leu Arg Ser Leu Gin Ala Phe Val Ala Val Ala 145 150 155 CAT GGA GCA GCA ACC CTG AGT CCC TAA His Gly Ala Ala Thr Leu Ser Pro 165 INFORMATION FOR SEQ ID NO:2: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 189 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Leu Gly Ser Arg Ala Val Met Leu Leu Leu Leu Leu Pro Trp Thr a a.

a.

-21 -20 25 A14 Gin Gly Arg Cys Gin Gin Leu Pro Leu Val Gly 30 Thr Asn Asp Val 35 45 Gly Leu Arg Asp 40 Leu Ile Phe Tyr Pro Ser Leu Leu Leu Gly Leu Ser 110 Gin Gin Ile Pro 125 Leu Arg Phe Lys 140 Ala Arg Val Phe Pro Lys Asp Ile 50 Gin Leu Ser Leu Ser 130 Arg Gly Ser Ser 5 Thr Leu Giu Giu Gly Asp Leu Gin 70 Ser Asp 85 Ala Gin Giu Gly Pro Ala Trp, Ala Trp Ser Gly Asp Glu Gly Cys Asp Arg Ile His le Phe Thr Leu His Ala 105 His His Trp 120 Trp Gin Arg 135 Phe Val Ala Ser Pro Thr Gin Ala His Giu Thr Pro Gin Gin Gly Gly Giu Ser Leu Giu Thr Leu Leu Val Ala 155 Ser Gin Pro Gin Ala 150 Thr Leu 165 INFORMATION FOR SEQ, ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 1203 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 113. .700 (ix) FEATURE: NAME/KEY: mat~peptide LOCATION: 176. .700 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: CGCTTAGAAG TCGGACTACA GAGTTAGACT CAGAACCAAA CAGGCCTGGT GCAGATCACA GAGCCAGCCA GATCTGAGAA GGAGGTGGAT AGGGGGTCCA GCAGGGAACA AG ATG *9

CTG

Leu -20

CAG

Gin 30 CAG Gln

CCA

35 Pro

AAA

Lys 40 45

GGA

Gly

CTG

Leu

CCT

Pro

CTA

Leu

CAA

Gin 125

CTC

Leu AGA GCA Arg Ala GCT GTG Ala Val 1 TCT CGG Ser Arg CAT ATG His Met GTG CCC Val Pro GAC AAC Asp Asn TAT AAG Tyr Lys CTC CCT Leu Pro AGC CAA Ser Gin CCC AGC Pro Ser AAG ATC Lys Ile 145 GTA ATA Vai Ile -15 CCT AGG Pro Arg AAT CTC Asn Leu AAT CTA Asn Leu COT ATC Arg Ile 50 AGC CAG Ser Gin CAC CTG His Leu GAT AGO Asp Ser CTC CTC Leu Leu 115 CTG AGT Leu Ser 130 CTT CGA Leu Arg

CTG

Leu

CCT

Pro

GC

Ala

GAA

Giu

GAT

Asp

CAA

Gin

GAC

Asp

CAA

Gin

OAT

Asp

CAG

Gin 135

GCC

Ala GCC CGG GTC TTT GCC CAC GGA GCA GCA ACT CTG ACT GAG CCC TrA GTG Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Thr Glu Pro Leu Val 160 165 170 CCA ACA GCT TAAGGATGCC CAGGTTCCCA TGGCTACCAT GATAAGACTA Pro Thr Ala 175 ATCTATCAGC CCAGACATCT ACCAG'N'AAT TAACCCATTA GGACTTGTGC TGTTCTTGTT TCGTTTGTTT TGCGTGAAGG GCAAGGACAC CATTATTAAA GAGAAAAGAA ACAAACCCCA GAGCAGGCAG CTGGCTAGAG AAAGGAGCTG GAGAAGAAGA ATAAAGTCTC GAGCCCTTGG CCTTGGAAGC GGGCAAGCAG CTGCGTGGCC TGAGGGGAAG GGGGCGGTGG CATCGAGAAA CTGTGAGAAA ACCCAGAGCA TCAGAAAAAG TGAGCCCAGG CTTTGGCCAT TATCTGTAAG 20 AAAAACAAGA AAAGGGGAAC ATTATACTTT CCTGGGTGGC TCAGGGAAAT GTGCAGATGC ACAGTACTCC AGACAGCAGC TCTGTACCG CCTGCTCTGT CCCTCAGTTC TAACAGAATC TAGTCACTAA GAACTAACAG GACTACCAAT ACGAACTGAC AAA Boo 860 920 980 1040 1100 1160 1203 9 9 9 9.99 .99.

9 99 .9 9*9999 9 9. 9 09 99 9.9.

9 999* 9* 9 .9 99 INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 196 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Leu Asp Cys Arg Ala Val Ile Met Leu 9t 9 99 9* 99 9 99 .9 -21 Thr -5 Cys -20 Gin Gly Trp Leu Leu Pro Trp Val Leu Ala Val Pro Arg Ser Ser Ser Pro Asp Trp Ala Gin Gin Gin Leu Ser Arg Asn His Met Asn Ala Pro Ala Thr Lys Asn Gin Gly Leu Gly Leu Cys 20 Leu Leu Ile Gin Gin Phe Met Arg Leu Ala Trp Asp Giu Giu Glu Giu Asn Val Pro Lys Asp Asn 65 Cys Glu Asp Giy Cys Cys Leu Gin Arg Ile Asp Ser Asp Ile Phe Asp Pro Arg Gly Leu Ala Phe Tyr Lys His Leu Leu Lys Gly Giu Pro Ala Leu Leu Gly 110 Leu Pro Asp Ser Pro 100 Leu Gin 115 Met Giu Gin Leu Pro Giu Asp His 120 His Thr Ser 105 Pro Arg Giu Leu Ser Gin Leu 6 Thr Gin Gin Met Pro Ser Leu Ser Ser Ser Gin Gin Trp Gin Arg Pro 125 130 135 Leu Leu Arg Ser Lys Ile Leu Arg Ser Leu Gin Ala Phe Leu Ala Ile 140 145 150 155 Ala Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Thr Glu Pro Leu 160 165 170 Val Pro Thr Ala 175 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 102 amino acids TYPE: amino acid STRANDEDNESS: not relevant 00 TOPOLOGY: linear sees (ii) MOLECULE TYPE: peptide 0OS* o* S(xi) SEQUENCE DESCRIPTION: SEQ ID Ser Cys Leu Gin Arg Ile His Gin Gly Leu Val Phe Tyr Glu Lys Leu S1 5 10 Leu Gly Ser Asp Ile Phe Thr Gly Glu Pro Ser Leu His Pro Asp Gly 20 25 Ser Val Gly Gin Leu His Ala Ser Leu Leu Gly Leu Arg Gin Leu Leu 35 40 Gin Pro Glu Gly His His Trp Glu Thr Glu Gin Thr Pro Ser Pro Ser 55 40 Pro Ser Gin Pro Trp Gin Arg Leu Leu Leu Arg Leu Lys Ile Leu Arg 65 70 75 *0 0 Ser Leu Gin Ala Phe Val Ala Val Ala Ala Arg Val Phe Ala His Gly 90 Ala Ala Thr Leu Ser Gin 100 INFORMATION FOR SEQ ID NO:6: SEQUENCE CHARACTERISTICS: LENGTH: 174 amino acids TYPE: amino acid STRANDEDNESS: not relevant TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 7 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Thr Pro Leu Gly Pro Ala Arg Ser ILeu Pro Gin Ser Phe-Leu-Leu Lys 1 5 10 0 '0 O*o.

o Cys Giu Leu Ser Gly Pro Phe Ala Gin 145 Leu Arg Leu Ser Leu Giu Ala Val 130 Arg Gin Cys His Ser Leu Ala 100 Asn Pro Ala Val Ala Ser Leu Tyr Pro Ile Thr Gly Tyr 165 Arg Lys Ile Ala His Lys Leu Gly Ile Gin Leu Arg 70 Gin Gly Leu Thr Leu Asp Trp Leu Gin 120 Gin Gly Ala 135 Giy Val Leu 150 Arg Gly Leu Gin 25 Leu Pro Gly Leu Thr 105 Met Met Val Arg Ala Asp Cys His Gin Ala Cys Leu Gin Ala 90 Leu Gin Giu Giu Ser Leu Gly Val 110 Ala Ser His Pro Leu Leu Ser His Ile Thr Ala Ala Arg Leu Giu Leu Ala INFORMATION FOR SEQ ID NO:7: SEQUENCE CHARACTERISTICS: LENGTH: 174 amino acids TYPE: amino acid STRANDEDNESS: not relevant TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Thr Pro Leu Giy Pro Thr Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys 1 5 10 Cys Leu Giu Gin Val Arg Lys Vai Gin Ala Asp Giy Thr Ala Leu Gin 25 Giu Arg Leu Cys Ala Ala His Lys Leu Cys His Pro Glu Giu Leu Val 40 Leu Leu Gly His Ala Leu Gly Ile Pro Gin Ala Pro Leu Ser Ser Cys 55 8 Ser Ser Gin Ala Leu Gin Leu Thr Gly Cys Leu Arg Gin Leu His Ser 70 75 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Ala Gly Ile Ser 90 Pro Glu Leu Ala Pro Thr Leu Asp Met Leu Gin Leu Asp Ile Thr Asp 100 105 110 Phe Ala Ile Asn Ile Trp Gin Gin Met Glu Asp Val Gly Met Ala Pro 115 120 125 Ala Val Pro Pro Thr Gin Gly Thr Met Pro Thr Phe Thr Ser Ala Phe 130 135 140 Gin Arg Arg Ala Gly Gly Thr Leu Val Ala Ser Asn Leu Gin Ser Phe S. 145 150 155 160 20 Leu Glu Val Ala Tyr Arg Ala Leu Arg His Phe Thr Lys Pro 165 170 INFORMATION FOR SEQ ID NO:8: 25 SEQUENCE CHARACTERISTICS: LENGTH: 177 amino acids TYPE: amino acid STRANDEDNESS: not relevant TOPOLOGY: linear MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys 1 5 10 Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin 20 25 Glu Lys Leu Val Ser Glu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu 35 40 Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu 55 Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin 70 75 Leu His Ser Gly Leu Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala 90 Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu 100 105 110 Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu 115 120 125 Arg His Leu Ala Gin Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu 130 135 140 9 Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp 145 150 155 160 Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly 165 170 175 Pro INFORMATION FOR SEQ ID NO:9: SEQUENCE CHARACTERISTICS: LENGTH: 178 amino acids TYPE: amino acid STRANDEDNESS: not relevant TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: 25 Val Pro Leu Val Thr Val Ser Ala Leu Pro Pro Ser Leu Pro Leu Pro S1 5 10 Arg Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Ala 25 Ser Gly Ser Val Leu Leu Glu Gln Leu Cys Ala Thr Tyr Lys Leu Cys 40 His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Lys 50 55 Ala Ser Leu Ser Gly Cys Ser Ser Gin Ala Leu Gin Gin Thr Gin Cys 70 75 Leu Ser Gin Leu His Ser Gly Leu Cys Leu Tyr Gin Gly Leu Leu Gin *85 90 S* Ala Leu Ser Gly Ile Ser Pro Ala Leu Ala Pro Thr Leu Asp Leu Leu 100 105 110 Gin Leu Asp Val Ala Asn Phe Ala Thr Thr Ile Trp Gin Gin Met Glu 115 120 125 Asn Leu Gly Val Ala Pro Thr Val Gin Pro Thr Gin Ser Ala Met Pro 130 135 140 Ala Phe Thr Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Ala Ile 145 150 155 160 Ser Tyr Leu Gin Gly Phe Leu Glu Thr Ala Arg Leu Ala Leu His His 165 170 175 Leu Ala INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 186 amino acids TYPE: amino acid STRANDEDNESS: not relevant TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID Ala Phe Pro Thr Pro Gly Pro Leu Gly Gly 1 5 10 Thr Ser Asn Arg Pro Pro Leu Thr Ser Ala 25 Ile Lys Phe Ile Leu Gly Lys Ile Ser Ala 40 Asp Lys Tyr Asn Lys Cys Glu Asp Ser Lys 50 55 Asn Leu Asn Leu Pro Lys Leu Ala Glu Lys 65 70 Arg Phe Asn Gin Glu Thr Cys Leu Thr Arg 85 90 Glu Phe Gin Ile His Leu Lys Tyr Leu Glu 100 105 Lys Asp Asn Ala His Ser Val Tyr Ile Ser 115 120 Thr Leu Arg Pro Met Asn Gin Ile Glu Val 130 135 Thr Asp Ala Ser Leu Gin Ala Leu Phe Lys 145 150 Lys His Thr Thr Ile His Leu Ile Leu Arg 165 170 Gin Phe Ser Leu Arg Ala Ile Arg Ile Met 180 185 INFORMATION FOR SEQ ID NO:11: SEQUENCE CHARACTERISTICS: LENGTH: 183 amino acids TYPE: amino acid STRANDEDNESS: not relevant TOPOLOGY: linear (ii) MOLECULE TYPE: peptide Asp Ser Lys Asp Asp Ala Asp Lys Met Glu Asp Phe Leu Arg Asn Glu Met Cys Glu Val Leu Ala Glu Asn Asp Arg Cys Phe Gin Ser 75 Ile Thr Thr Gly Leu Gin Ser Asn Tyr Glu Gly Asn 110 Thr Lys His Leu Leu Gin 125 Thr Thr Pro Asp Pro Thr 140 Ser Gin Asp Lys Trp Leu 155 160 Arg Leu Glu Asp Phe Leu 175 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Ala Phe Pro Thr Pro Gly Pro Leu Gly Gly Asp Ala Thr Ser-Asn Arg 1 5 10 Leu Leu Lys Pro Glu Tyr Lys Lys Val 145 Asn Ala Asp Lys Met Glu Ala Leu Lys Lys Giu Lys Giu Ala Leu Ala Lys Asp Gly Cys Phe 70 Arg Ile Thr Thr Gly Gin Asp Lys Tyr Glu 105 Ser Thr Asn Val Leu 120 Asp Glu Val Thr Ile 135 Ser Cys Ser His Arg 150 Leu Arg Arg Leu Glu 170 Lys Asn Leu Phe Phe Glu 110 Leu Thr Glu Tyr Ile Tyr Asn Asn Leu Asn Gin Gin Ile Asn Ala Lys Arg Val Glu Ala His 160 Leu Arg 175 Asp Phe Leu Gin Leu Arg Ala Val Arg Ile Met 180 40 INFORMATION FOR SEQ ID NO:12: Wi SEQUENCE CHARACTERISTICS: LENGTH: 188 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID N0:12: Ala Phe Pro Ala Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala 1 5 10 Ala Pro His Arg Gin Pro Leu Thr Ser Ser Giu Arg Ile Asp Lys Gin 25 Ile Arg Tyr Ile Leu Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr Cys 40 12 Asn Lys Ser Asn Met Cys Glu Ser Ser Lys Giu Ala Leu Ala Glu Asn 55 Asn Leu Asn Leu Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Gin Ser 70 75 Gly Phe Asn Glu Giu Thr Cys Leu Val Lys Ile Ile Thr Gly Leu Leu 90 Glu Phe Glu Val Tyr Leu Giu Tyr Leu Gin Asn Arg Phe Glu Ser Ser 100 105 110 Glu Glu Gin Ala Arg Ala Val Gin Met Ser Thr Lys Val Leu Ile Gin 115 120 125 Phe Leu Gin Lys Lys Ala Lys Asn Leu' Asp Aia Ile Thr Thr Pro Asp 130 135 140 Pro Thr Thr Asn Ala Ser Leu Leu Thr Lys Leu Gin Ala Gin Asn Gin *145 150 155 160 Trp Leu Gin Asp Met Thr Thr His Leu Ile Leu Arg Ser Phe Lys Giu *165 170 175 Phe Leu Gin Ser Ser Leu Arg Ala Leu Arg Gin Met 180 185 INFORMATION FOR SEQ ID NO:13: 30(i) SEQUENCE CHARACTERISTICS: LENGTH: 184 amino acids TYPE: amino acid STR.ANDEDNESS: not relevant *3 D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Ala Phe Pro Thr Pro Gly Pro Leu Gly Glu Asp Phe Lys Asn Asp Thr 1 5 10 Thr Pro Ser Arg Leu Leu Leu Thr Thr Pro Glu Lys Thr Glu Ala Leu 25 Ile Lys His Ile Val Asp Lys Ile Ser Ala Ile Arg Lys Giu Ile Cys 40 Giu Lys Asn Asp Giu Cys Glu Asn Ser Lys Glu Thr Leu Ala Glu Asn 55 Lys Leu Lys Leu Pro Lys Met Glu Giu Lys Asp Gly Cys Phe Gin Ser 70 75 Gly Phe Asn Gin Ala Ile Cys Leu Ile Lys Thr Thr Ala Gly Leu Leu 8590 Glu Tyr Gin Ile Tyr Leu Asp Phe Leu Gin Asn Glu Phe Glu Gly Asn 100 105 110 13 Gin Giu Thr Val Met Glu Leu Gin Ser Ser Ile Arg Thr Leu Ile Gin 115 120 125 Ile Leu Lys Giu Lys Ile Ala Giy Leu Ile Thr Thr Pro Aia'Thr His 130 135 140 Thr Asp Met Leu Giu Lys Met Gin Ser Ser Asn Giu Trp Val Lys Asn 145 150 155 160 Ala Lys Val Ile Ile Ile Leu Arg Ser Leu Giu Asn Phe Leu Gin Phe 165 170 175 Ser Leu Arg Ala Ile Arg Met Lys 180 INFORMATION FOR SEQ ID NO:14: SEQUENCE CHARACTERISTICS: LENGTH: 188 amino acids TYPE: amino acid STRANDEDNESS: not relevant TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Ala Phe Pro Thr Ser Gin Val Arg Arg Gly Asp Phe Thr Glu Asp Thr 1 5 10 *Thr Pro Asn Arg Pro Val Tyr Thr Thr Ser Gin Val Gly Gly Leu Ile 25 Thr His Val Leu Trp, Glu Ile Val Giu Met Arg Lys Glu Leu Cys Asn 404 Giy Asn Ser Asp Cys Met Asn Asn Asp Asp Ala Leu Ala Glu Asn Asn 55 40 Leu Lys Leu Pro Giu Ile Gin Arg Asn Asp Gly Cys Tyr Gin Thr Gly *:65 70 75 Tyr Asn Gin Glu Ile Cys Leu Leu Lys Ile Ser Ser Gly Leu Leu Giu 85 90 Tyr His Ser Tyr Leu Glu Tyr Met Lys Asn Asn Leu Lys Asp Asn Lys 100 105 110 Lys Asp Lys Ala Axg Val Leu Gin Arg Asp Thr Giu Thr Leu Ile His 115 120 125 Ile Phe Asn Gin Giu Val Lys Asp Leu His Lys Ile Val Leu Pro Thr 130 135 140 Pro Ile Ser Asn Ala Leu Leu Thr Asp Lys Leu Giu Ser Gin Lys Glu 145 150 155 160 TrP Leu Arg Thr Lys Thr Ile Gin Phe Ile Leu Lys Ser Leu Giu Glu 165 170 175 Phe Leu Lys Val Thr Leu Arg Ser Thr Arg Gin Thr 180 185 14 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 178 amino acids TYPE: amino acid STRANDEDNESS: not relevant TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID Ala Pro Leu Ala Glu Leu Ser Gly Asp His Asp Phe Gin Leu Phe Leu 1 5 10 His Lys Asn Leu Glu Phe Thr Arg Lys Ile Arg Gly Asp Val Ala Ala 20 20 25 Leu Gin Arg Ala Val Cys Asp Thr Phe Gin Leu Cys Thr Glu Glu Glu 35 40 25 Leu Gin Leu Val Gin Pro Asp Pro His Leu Val Gin Ala Pro Leu Asp 50 55 Gin Cys His Lys Arg Gly Phe Gin Ala Glu Val Cys Phe Thr Gin Ile 70 75 S 30 Arg Ala Gly Leu His Ala Tyr His Asp Ser Leu Gly Ala Val Leu Arg 85 90 Leu Leu Pro Asn His Thr Thr Leu Val Glu Thr Leu Gin Leu Asp Ala 100 105 110 Ala Asn Leu Ser Ser Asn Ile Gin Gin Gin Met Glu Asp Leu Gly Leu 115 120 125 40 Asp Thr Val Thr Leu Pro Ala Glu Gin Arg Ser Pro Pro Pro Thr Phe 130 135 140 Ser Gly Pro Phe Gin Gin Gin Val Gly Gly Phe Phe Ile Leu Ala Asn 145 150 155 160 Phe Gin Arg Phe Leu Glu Thr Ala Tyr Arg Ala Leu Arg His Leu Ala 165 170 175 Arg Leu INFORMATION FOR SEQ ID NO:16: SEQUENCE CHARACTERISTICS: LENGTH: 185 amino acids TYPE: amino acid STRANDEDNESS: not relevant TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Thr Arg Gly Lys Leu Pro Asp Ala Pro Giu Phe Giu Lys Asp Leu Leu Soo 0 0e

G*

a

S

1 Ile Asp Ala Gly Gly Gly Leu Tyr Leu 145 Met Gin Leu Ile Leu Phe Lys Gly Ser 130 Lys Glu Ile Gly Asn Leu 75 Phe Giu Lys Leu Phe 155 Val Arg Ala Cys Asp so Phe Thr His Gly Ala 160 Pro 10 Asp Val Thr Pro Asp Val His Asp Lys

Claims (24)

1. An isolated or recombinant polynucleotide encoding a polypeptide comprising: a) at least 148 contiguous amino acids from the mature polypeptide of SEQ ID NO: 2; b) at least 17 contiguous amino acids from the mature polypeptide of SEQ ID NO: 4; or c) at least 30 contiguous amino acids from the mature polypeptide of SEQ ID NO:

2. The polynucleotide of Claim 1, encoding the mature polypeptide of: a) SEQ ID NO: 2; b) SEQ ID NO: 4; or c) SEQ ID NO:

3. The polynucleotide of Claim 1, which hybridizes under stringent wash conditions of at least 650 C and less than about 150 mM salt to the complement of at least contiguous nucleotides of: a) GTG CCT GGG GGC AGC AGC CCT GCC TGG ACT CAG TGC CAG CAG CTT TCA CAG AAG CTC TGC ACA CTG GCC TGG AGT CCA CTA GTG GGA CAC ATG GAT CTA AGA GAA GAG GGA GAT GAA ACA AAT GAT GTT CCC CAT ATC CAG TGT GGA GAT GGC TGT GAC GGA CTC AGG GAC AAC AGT CAG TTC TGC TTG CAA AGG ATC CAC CTG ATT TTT TAT GAG AAG CTG CTA GGA TCG GAT ATT TTC ACA CCT TCT CTG CTC CCT GAT AGC CCT GTG GCG CAG CTT CAT GCC CTG GGC CTC AGC CAA CTC CTG CAG CCT GAG GGT CAC CAC TGG CAG CAG ATT CCA AGC CTC AGT CCC AGC CAG CCA TGG CAG CGT CTC CGC TTC AAA ATC CTT CGC AGC CTC CAG GCC TTT GTG GCT GCC CGG GTC TTT GCC CAT GGA GCA GCA ACC CTG AGT CCC; or c GCA CAT GAG ACT CCC CAA CAG GGT GGG GAG TCC CTA GAG ACT CTC CTT GTA GCC b) GTG CCT AGG AGT AGC AGT CCT GAC TGG GCT CAG TGC 62 CAG CCA AAA GGA CTG CCT CTA CAA CTC GCC CCA CAG GCG AAT CTC GCT GCT GGA CAG CGT CGG ACA CTC TCT CGG GGA CAT ATG AAT GTG CCC AAG GAC AAC TTT TAT AAG CTA CTC CCT CTC AGC CAA ATG CCC AGC TCC AAG ATC GTC TTT GCC GCT. AAT CTC TGC ATG CTA GCC TGG AAC AAT CTA CTA AGA GAA GAA GAG GAT CGT ATC CAG TGT.GAA GAT GGT TGT AGC CAG TTC TGC TTG CAA AGG ATC CAC CTG CTT GAC TCT GAC ATC.TTC GAT AGC CCC ATG GAG CAA CTT CAC CTC CTC CAG CCA GAG GAT CAC CCC CTG AGT TCT AGT CAG CAG TGG CAG CTT CGA AGC CTC CAG GCC TTT TTG CAC GGA GCA GCA ACT CTG ACT GAG GCA CAT GCA GAA GAG ACT GAC CCA CAA CGC CAA GGT AAA GGG GAG ACC TCC CTA CGG GAG ACC CGC CCC CTT GCC ATA GCT CCC TTA GTG

4. An expression vector comprising the polynucleotide of Claim 1.

5. An isolated host cell comprising the expression vector of Claim 4.

6. A method for making a polypeptide comprising culturing the host cell of Claim 5 under conditions in which the polynucleotide is expressed.

7. A method for detecting a polynucleotide of Claim 1 in a sample, comprising contacting the sample with a probe comprising at least 25 contiguous nucleotides of: @0 0 0 *000 0 0 9 00*0 L a) TGC CAG CCA CTA ACA AAT GGA CTC CTG ATT CCT TCT 30 CTG GGC CAG CAG CTC CGC GCC CGG GTG CCT GGG GGC AGC AGC CCT GCC TGG ACT CAG CAG CTT TCA CAG AAG CTC TGC ACA CTG GCC TGG AGT GCA CAT GTG GGA CAC ATG GAT CTA AGA GAA GAG GGA GAT GAA GAG ACT GAT GTT CCC CAT ATC CAG TGT GGA GAT GGC TGT GAC CCC CAA AGG GAC AAC AGT CAG TTC TGC TTG CAA AGG ATC CAC CAG GGT TTT TAT GAG AAG CTG CTA GGA TCG GAT ATT TTC ACA GGG GAG CTG CTC CCT GAT AGC CCT GTG GCG CAG CTT CAT GCC TCC CTA CTC AGC CAA CTC CTG CAG CCT GAG GGT CAC CAC TGG GAG ACT ATT CCA AGC CTC AGT CCC AGC CAG CCA TGG CAG CGT CTC CTT TTC AAA ATC CTT CGC AGC CTC CAG GCC TTT GTG GCT GTA GCC GTC TTT GCC CAT GGA GCA GCA ACC CTG AGT CCC; or b) GTG CCT AGG AGT AGC AGT CCT GAC TGG GCT CAG TGC 63 CAG CAG CCA GCG AAA AAT GGA CTC CTG GCT CCT GCT CTA GGA CAA CAG CTC CGT GCC CGG CCA ACA CTC TCT CGG AAT CTC TGC ATG GGA CAT ATG AAT CTA CTA AGA AAT GTG CCC CGT ATC CAG TGT AAG GAC AAC AGC CAG TTC TGC TTT TAT AAG CAC CTG CTT GAC CTA CTC CCT GAT AGC CCC ATG CTC AGC CAA CTC CTC CAG CCA ATG CCC AGC CTG AGT TCT AGT TCC AAG ATC CTT CGA AGC CTC GTC TTT GCC CAC GGA GCA GCA GCT; CTA GCC TGG GAA GAA GAG GAA GAT GGT TTG CAA AGG TCT GAC ATC GAG CAA CTT GAG GAT CAC CAG CAG TGG CAG GCC TTT ACT CTG ACT AAC GCA CAT GCA GAT GAA GAG ACT TGT GAC CCA CAA ATC CGC CAA GGT TTC AAA GGG GAG CAC ACC TCC CTA CCC CGG GAG ACC CAG CGC CCC CTT TTG GCC ATA GCT GAG CCC TTA GTG under conditions suitable for the formation of a duplex.

8. A kit for detecting a polynucleotide of Claim 1, comprising a compartment containing a probe comprising: a) GTG CCT GGG GGC AGC AGC CCT GCC TGG ACT CAG TGC CAG CAG CTT TCA CAG AAG CTC TGC ACA CTG GCC TGG AGT GCA CAT- CCA CTA GTG GGA CAC ATG GAT CTA AGA GAA GAG GGA GAT GAA GAG ACT ACA AAT GAT GTT CCC CAT ATC CAG TGT GGA GAT GOC TGT GAC CCC CAA GGA CTC AGG GAC AAC AGT CAG TTC TGC TTG CAA AGG ATC CAC CAG GGT CTG ATT TTT TAT GAG AAG CTG CTA GGA TCG GAT ATT TTC ACA GGG GAG CCT TCT CTG CTC CCT GAT AGC CCT GTG GCG CAG CTT CAT GCC TCC CTA CTG GGC CTC AGC CAA CTC CTG CAG CCT GAG GGT CAC CAC TGG GAG ACT CAG CAG ATT CCA AGC CTC AGT CCC AGC CAG CCA TGG CAG CGT CTC CTT CTC CGC TTC AAA ATC CTT CGC AGC CTC CAG GCC TTT GTG GCT GTA GCC GCC CGG GTC TTT GCC CAT GGA GCA GCA ACC CTG AGT CCC; or b) GTG CCT AGG ACT AGC ACT CCT GAC TGG GCT CAG TGC ego* go o 000 0*06 S640 o 0 6000 S a SS *0 0 0 @0 5 S SOS. @0 0 0 CAG CAG CTC CCA GCG GGA AAA AAT AAT CGA CTC AAG CTG CCT TTT CCT GCT CTA CTA GGA CTC CAA CAG ATG CTC CGT TCC 30 GCC CGC GTC CCA ACA GCT TCT CGG AAT CTC CAT ATG AAT CTA GTC CCC CGT ATC GAC AAC AGC CAG TAT AAG CAC CTG CTC CCT GAT AGC AGC CAA CTC CTC CCC AGC CTG AGT AAG ATC CTT CGA TTT GCC CAC GGA TGC ATG CTA CTA AGA GAA CAG TGT GAA TTC TGC TTG CTT CAC TCT CCC ATG GAG CAG CCA GAG TCT ACT CAG AGC CTC CAG GCA GCA ACT GCC TGC AAC GCA GAA GAG GAT CAA GAT GGT TCT GAC CAA ACG ATC CGC GAC ATC TTC AAA CAA CTT CAC ACC CAT CAC CCC CGG CAC TGG CAG CGC GCC TTT TTG GCC CTG ACT GAG CCC CAT GCA GAG ACT CCA CAA CAA GGT GGG GAG TCC CTA GAG ACC CCC CTT ATA GCT TTA GTG 64 that hybridizes, under stringent hybridization conditions of at least 650 C and less than about 150 mM salt, to at least 17 contiguous nucleotides of a polynucleotide of Claim 1 to form a duplex.

9. The kit of Claim 8, wherein said probe is detectably labeled.

A binding compound which: 1) specifically binds to the mature polypeptide of SEQ ID NO: 2; 2) specifically binds to the mature polypeptide of SEQ ID NO: 4; 3) specifically binds to the mature polypeptide of SEQ ID NO: 4) is raised against a purified or recombinantly produced human IL-B30 protein; is raised against a purified or recombinantly produced mouse IL-B30 protein; or 6) is raised against a purified or recombinantly produced pig IL-B30 protein.

11. The binding compound of Claim 10, wherein said binding compound is: 1) an antibody molecule; 2) a monoclonal antibody; 3) a Fab; 4) a F(ab)2; 5) a polyclonal antiserum; 6) detectably labeled; 7) sterile; or 8) in a buffered composition. 65

12. A method using the binding compound of Claim comprising contacting said binding compound with a biological sample comprising an antigen, wherein said contacting results in formation of a binding compound:antigen complex.

13. The method of Claim 12, wherein said biological sample is from a human, and <wherein said binding compound is an antibody. .0

14. A detection kit comprising said binding compound of Claim 10 or Claim 11, and a) instructional material for the use of said binding compound for said detection; or b) a compartment providing segregation of said binding compound.

A substantially pure or isolated polypeptide, which comprises: !0 a) at least 148 contiguous amino acids from the mature polypeptide of SEQ ID NO: 2; b) at least 17 contiguous amino acids from the mature polypeptide of SEQ ID NO: 4; or c) at least 30 contiguous amino acids from the mature polypeptide of SEQ ID NO: 0 0 0 0 0 0

16. The a) b) c) d) e) f) polypeptide of Claim 15, which: is a soluble polypeptide; is detectably labeled; is in a sterile composition; is in a buffered composition; binds to a cell surface receptor; is recombinantly produced; or 66 g) has a naturally occurring polypeptide sequence.

17. Use of an agonist or antagonist of a mammalian IL- wherein said mammalian IL-B30 comprises the mature polypeptide of SEQ ID NO: 2, 4, or 5 in the manufacture of a medicament for modulating physiology or development of a cell or tissue culture cells.

18. The use according to Claim 17, wherein: a) said medicament comprises an agonist or antagonist of G-CSF and/or IL-6; or b) said medicament comprises a binding composition which specifically binds to the mature polypeptide of SEQ ID NO: 2, 4 or 6.

19. An isolated or recombinant polynucleotide encoding a polypeptide comprising the mature polypeptide of SEQ ID NO: 2.

20. A substantially pure or isolated polypeptide comprising the mature polypeptide of SEQ ID NO: 2.

21. A polypeptide produced by the method of Claim 6.

22. A fusion polypeptide comprising a polypeptide of Claim 15 and a homologous or heterologous polypeptide segment.

23. A method of modulating physiology or development of a 30 cell or tissue culture cells comprising contacting the cell or tissue culture cells with an agonist or antagonist of a mammalian IL-B30, wherein the mammalian comprises the mature polypeptide of SEQ ID NO: 2, 4, or 67

24. The method of Claim 23 wherein the agonist or antagonist comprises: a) an agonist or antagonist of G-CSF and/or IL-6; or b) a binding composition which specifically binds to the mature polypeptide of SEQ ID NO: 2, 4, or 6. Dated this 26th day of February 2004 SCHERING CORPORATION By their Patent Attorneys GRIFFITH HACK ft ft